<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children - Perez Chacon, G - 2021 | Cochrane Library</title> <meta content="Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children - Perez Chacon, G - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013682.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children - Perez Chacon, G - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013682.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013682.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children" name="citation_title"/> <meta content="Gladymar Perez Chacon" name="citation_author"/> <meta content="gladymar.perez@telethonkids.org.au" name="citation_author_email"/> <meta content="Jessica Ramsay" name="citation_author"/> <meta content="Telethon Kids Institute" name="citation_author_institution"/> <meta content="Christopher G Brennan-Jones" name="citation_author"/> <meta content="The University of Western Australia" name="citation_author_institution"/> <meta content="Marie J Estcourt" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Peter Richmond" name="citation_author"/> <meta content="Patrick Holt" name="citation_author"/> <meta content="The University of Western Australia" name="citation_author_institution"/> <meta content="Tom Snelling" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD013682.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013682.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013682.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013682.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; *Eczema; *Hypersensitivity, Immediate; Pertussis Vaccine [adverse effects]; *Whooping Cough" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013682.pub2&amp;doi=10.1002/14651858.CD013682.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="uQyIsxpV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013682\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013682\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013682.pub2",title:"Whole\\u2010cell pertussis vaccine in early infancy for the prevention of allergy in children",firstPublishedDate:"Sep 6, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Tobacco Addiction Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013682.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013682.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013682.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013682.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013682.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013682.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013682.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013682.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013682.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013682.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3330 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013682.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/appendices#CD013682-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/supinfo/CD013682StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/supinfo/CD013682StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Gladymar Perez Chacon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0005">Jessica Ramsay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0006">Christopher G Brennan-Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0007">Marie J Estcourt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0008">Peter Richmond</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0009">Patrick Holt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information#CD013682-cr-0010">Tom Snelling</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information/en#CD013682-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013682.pub2">https://doi.org/10.1002/14651858.CD013682.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013682-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013682-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013682-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013682-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013682-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013682-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013682-abs-0001" lang="en"> <section id="CD013682-sec-0001"> <h3 class="title" id="CD013682-sec-0001">Background</h3> <p>Atopic diseases are the most common chronic conditions of childhood. The apparent rise in food anaphylaxis in young children over the past three decades is of particular concern, owing to the lack of proven prevention strategies other than the timely introduction of peanut and egg. Due to reported in vitro differences in the immune response of young infants primed with whole‐cell pertussis (wP) versus acellular pertussis (aP) vaccine, we systematically appraised and synthesised evidence on the safety and the potential allergy preventive benefits of wP, to inform recommendation for future practice and research. </p> </section> <section id="CD013682-sec-0002"> <h3 class="title" id="CD013682-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of wP vaccinations in comparison to aP vaccinations in early infancy for the prevention of atopic diseases in children. </p> </section> <section id="CD013682-sec-0003"> <h3 class="title" id="CD013682-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials, Ovid MEDLINE, Embase, and grey literature. The date of the search was 7 September 2020. </p> </section> <section id="CD013682-sec-0004"> <h3 class="title" id="CD013682-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) that reported the occurrence of atopic diseases, and RCTs only to assess safety outcomes. To be included studies had to have at least six months follow‐up, and involve children under 18 years old, who received a first dose of either wP (experimental intervention) or aP (comparator) before six months of age. </p> </section> <section id="CD013682-sec-0005"> <h3 class="title" id="CD013682-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened studies for eligibility, extracted the data, and assessed risk of bias using standard Cochrane methods. We assessed the certainty of the evidence using GRADE. Our primary outcomes were diagnosis of IgE‐mediated food allergy and all‐cause serious adverse events (SAEs). Secondary outcomes included: diagnosis of not vaccine‐associated anaphylaxis or urticaria, diagnosis of asthma, diagnosis of allergic rhinitis, diagnosis of atopic dermatitis and diagnosis of encephalopathy. Due to paucity of RCTs reporting on the atopic outcomes of interest, we assessed a broader outcome domain (cumulative incidence of atopic disease) as specified in our protocol. We summarised effect estimates as risk ratios (RR) and 95% confidence intervals (CI). Where appropriate, we pooled safety data in meta‐analyses using fixed‐effect Mantel‐Haenszel methods, without zero‐cell corrections for dichotomous outcomes. </p> </section> <section id="CD013682-sec-0006"> <h3 class="title" id="CD013682-sec-0006">Main results</h3> <p>We identified four eligible studies reporting on atopic outcomes, representing 7333 children. Based on a single trial, there was uncertain evidence on whether wP vaccines affected the risk of overall atopic disease (RR 0.85, 95% CI 0.62 to 1.17) or asthma only (RR 1.04, 95% CI 0.59 to 1.82; 497 children) by 2.5 years old.Three NRSIs were judged to be at serious or critical risk of bias due to confounding, missing data, or both, and were ineligible for inclusion in a narrative synthesis.  </p> <p>We identified 21 eligible studies (137,281 children) that reported the safety outcomes of interest. We judged seven studies to be at high risk of bias and those remaining, at unclear risk.  </p> <p>The pooled RR was 0.94 for all‐cause SAEs (95% CI 0.78 to 1.15; I<sup>2</sup> = 0%; 15 studies, 38,072 children). For every 1000 children primed with a first dose of wP, 11 had an SAE. The corresponding risk with aP was 12 children (95% CI 9 to 13). The 95% CI around the risk difference ranged from three fewer to two more events per 1000 children, and the certainty of the evidence was judged as moderate (downgraded one level for imprecision). </p> <p>No diagnoses of encephalopathy following vaccination were reported (95% CI around the risk difference ‐ 5 to 12 per 100,000 children; seven primary series studies; 115,271 children). The certainty of the evidence was judged as low, since this is a serious condition, and we could not exclude a clinically meaningful difference. </p> </section> <section id="CD013682-sec-0007"> <h3 class="title" id="CD013682-sec-0007">Authors' conclusions</h3> <p>There is very low‐certainty evidence that a first dose of wP given early in infancy, compared to a first dose of aP, affects the risk of atopic diseases in children. The incidence of all‐cause SAEs in wP and aP vaccinees was low, and no cases of encephalopathy were reported. The certainty of the evidence was judged as moderate for all‐cause SAEs, and low for encephalopathy. </p> <p>Future studies should use sensitive and specific endpoints of clinical relevance, and should be conducted in settings with high prevalence of IgE‐mediated food allergy. Safety endpoints should prioritise common vaccine reactions, parental acceptability, SAEs and their potential relatedness to the dose administered. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013682-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013682-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013682-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013682-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013682-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013682-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013682-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013682-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013682-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013682-abs-0002" lang="en"> <h3>Can a first dose of whole‐cell whooping cough vaccine given before six months old prevent allergic diseases in childhood? </h3> <p><b>What are allergic diseases?</b> </p> <p>Allergic diseases are among the most common persistent illnesses in children. They are caused by the immune system reacting abnormally to otherwise harmless substances such as foods and pollens. Food allergies are of increasing concern as the number of cases reported in a number of high‐income countries over the past 30 years appears to have increased. </p> <p><b>Why we did this Cochrane Review?</b> </p> <p>The only proven preventive strategy against food allergies is early introduction of peanut and egg into the infant diet. However, a recent study found that food allergies appeared less common in children who had received one or more doses of whole‐cell (wP) whooping cough vaccine in early infancy than in those who had received acellular (aP) whooping cough vaccines only. That study could not determine whether the apparently lower risk of allergy was because of the wP vaccine, or whether it was because of other potential differences between wP and aP‐vaccinated children, as the vaccines were not randomly assigned. Therefore, a Cochrane Review was required to identify any evidence of wP as a food allergy prevention strategy. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared wP versus aP vaccination in babies younger than six months. We were interested in comparing babies vaccinated with wP vaccines and those vaccinated with aP vaccines, with respect to: </p> <p>1. how many went on to develop food allergy, asthma or serious (and potentially life‐threatening) allergic reactions; </p> <p>2. how many had serious unwanted events following vaccination; and,</p> <p>3. how many had encephalopathy, a serious yet uncommon condition affecting the brain.</p> <p>To compare rates of encephalopathy and other serious unwanted events, we looked for studies in which babies were given wP or aP vaccines at random (randomised controlled trials (RCTs)). To compare rates of allergic diseases, we also looked for studies where wP or aP vaccines were not given at random (non‐randomised studies of interventions (NRSIs)). In either case, studies lasted for at least six months. </p> <p><b>Search date</b> </p> <p>We included evidence published up to September 2020.</p> <p><b>What we found</b> </p> <p>Investigation 1 </p> <p>We found four studies (7333 children) carried out in Sweden (one), Australia (two) and the UK (one) that looked at the effect of whooping cough vaccines on allergic diseases. As we found little reliable data about the risk of food allergy after whooping cough vaccine, we decided to look at the risk of any allergic disease. Within 2.5 years of receiving a whooping cough vaccine (one RCT), 37/137 children vaccinated with wP, and 114/360 vaccinated with aP were diagnosed with at least one allergic disease. During the same period 15/137 vaccinated with wP and 38/360 vaccinated with aP were diagnosed with asthma specifically. No studies assessed serious or potentially life‐threatening allergic reactions. </p> <p>Investigations 2 &amp; 3 </p> <p>Low numbers of serious unwanted effects were reported for all groups (15 studies, 38,072 children). For every 1000 babies vaccinated with a first dose of wP, 11 had at least one serious unwanted effect. The risk for those who received aP vaccines was 12 children. No cases of encephalopathy were identified in either group (seven studies, 115,271 children). </p> <p><b>How reliable are these findings?</b> </p> <p>One RCT reporting on whooping cough vaccines and allergic diseases included few children, and was carried out in a country with low levels of allergic disease. Therefore, it remains very uncertain whether a first dose of wP does or does not decrease the risk of allergic diseases. </p> <p>Very few children experienced serious unwanted effects. We are uncertain whether there is a difference in the risk of serious unwanted effects in children vaccinated with a first dose of wP, compared with aP, but any difference is likely to be small. No cases of encephalopathy following vaccination were reported. Because this is a serious outcome, the certainty of the evidence was judged to be low. </p> <p><b>Key messages</b> </p> <p>Ongoing and future studies may change our conclusions and provide more definitive evidence. The data reviewed suggest that wP is safe and support its continued use in countries where it is still recommended for preventing whooping cough. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013682-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013682-sec-0130"></div> <h3 class="title" id="CD013682-sec-0131">Implications for practice</h3> <section id="CD013682-sec-0131"> <p> <ul id="CD013682-list-0022"> <li> <p>The evidence on the effect of a first dose of whole‐cell pertussis (wP) vaccine on the cumulative incidence of atopic diseases at 2.5 years old is very uncertain. However, an ongoing randomised controlled trial (RCT) could change this conclusion, at least for the prevention of early onset IgE‐mediated food allergy in settings with high prevalence. </p> </li> <li> <p>The incidence of serious adverse events (SAEs) following immunisation in infants primed with a first dose of wP versus acellular pertussis (aP) vaccine is low. There is moderate‐certainty evidence that a first or subsequent doses of wP do not reduce/increase the risk of SAEs. Therefore, there is no evidence to suggest that they are not safe for the prevention of pertussis in countries where they are currently recommended. </p> </li> </ul> </p> </section> <h3 class="title" id="CD013682-sec-0132">Implications for research</h3> <section id="CD013682-sec-0132"> <p> <ul id="CD013682-list-0023"> <li> <p>Large, well‐conducted RCTs are needed to investigate the possible allergy protective benefits of a first dose of wP given before six months old, ideally in populations with high prevalence of IgE‐mediated food allergy. </p> </li> <li> <p>Non‐randomised studies of interventions (NRSIs) using a target trial method may still be valuable. While confounding by targeted intervention is unlikely in NRSIs of historical cohorts, investigators still need to pay close attention to mitigating the risk of confounding as well as selection of specific endpoints. </p> </li> <li> <p>Future allergy trials should not only assess reactogenicity, tolerability and parental acceptability of a first dose of wP compared to aP, but also the relative frequency of SAEs and in particular, the potential relatedness to the dose administered. </p> </li> <li> <p>The selection of endpoints in future RCTs conceived to assess whether a first dose of wP may decrease the risk of IgE‐mediated food allergy, should not only prioritise the performance of oral food challenge with standardised stopping criteria, but also include diagnostic approaches in which IgE‐mediated food allergy is highly probable, based on a combination of parental reported, clinician‐diagnosed food allergic reaction coupled with evidence of IgE‐mediated sensitisation. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013682-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013682-sec-0008"></div> <div class="table" id="CD013682-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants younger than six months of age<br/><b>Setting:</b> paediatric and immunisation clinics, vaccine treatment units attached to academic institutions and healthcare centres. The trials were carried out in 11 countries across North and South America, Europe, Sub‐Saharan Africa and South East Asia<br/><b>Intervention:</b> first dose of whole‐cell pertussis vaccine (wP)<br/><b>Comparison:</b> first dose of acellular pertussis vaccine (aP) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow‐up</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with first dose of acellular pertussis vaccine (aP)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with first dose of whole‐cell pertussis vaccine (wP)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence of atopic disease at 2.5 years old</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>It remains uncertain whether a first dose of wP, compared to aP, may prevent atopic diseases (RR 0.85, 95% CI 0.62 to 1.17). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of IgE‐mediated food allergy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0<br/>(studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>One study reported this (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>) as part of a broader outcome domain (i.e. cumulative incidence of atopic disease at 2.5 years old; reported in row above). However, it was not possible to obtain the data on incidence of IgE‐mediated food allergy specifically by study arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of asthma</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>It remains uncertain whether a first dose of wP, compared to aP, may prevent asthma (RR 1.04, 95% CI 0.59 to 1.82). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of anaphylaxis (not vaccine associated)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>38,072<br/>(15 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.78 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1,000<br/>(3 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diagnosis of encephalopathy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115,271 <br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 100,000<br/>(5 fewer to 12 more)<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval;<b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the evidence by one level due to indirectness (study carried out in the late 1990s, in a country with low prevalence of IgE‐mediated food allergy) </p> <p><sup>2</sup> We downgraded the evidence by two levels due to imprecision (single study, statistically underpowered to detect a reduction in its chosen endpoints, except for a very large reduction &gt; 50%) </p> <p><sup>3</sup> We downgraded by one level for indirectness, as it is plausible that children diagnosed with 'asthma' by 2.5 years old, may have been 'transient (episodic) wheezers'. We believe that the risk of developing transient wheeze in early childhood is unlikely to be affected by wP priming </p> <p><sup>4</sup> We downgraded the certainty of the evidence by one due to imprecision (the 95% CI ranges from a potential decreased to a potential increased risk, unlikely to be clinically meaningful) </p> <p><sup>5</sup> Although the 95% CI around the absolute difference is narrow, we could not rule out a clinically meaningful difference and therefore, we rated down two levels for imprecision </p> <p><sup>6</sup> 95% CI calculated using the score method (<a href="./references#CD013682-bbs2-0112" title="NewcombeRG . Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in medicine1998;17(8):873-90. [PMID: 9595617]">Newcombe 1998</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013682-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013682-sec-0009"></div> <p>See <a href="./appendices#CD013682-sec-0136">Appendix 1</a> for a glossary defining some of the scientific terms used throughout this review. </p> <section id="CD013682-sec-0010"> <h3 class="title" id="CD013682-sec-0010">Description of the condition</h3> <p>Allergic (atopic) diseases are the most common non‐communicable diseases of childhood (<a href="./references#CD013682-bbs2-0119" title="PrescottSL . Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. Journal of Allergy and Clinical Immunology2013;131(1):23–30. [DOI: 10.1016/j.jaci.2012.11.019]">Prescott 2013</a>). The 'atopic march' is typically described as commencing in early childhood with the development of eczema (atopic dermatitis), followed by immunoglobulin E (IgE)‐mediated food allergy and later, asthma and hay fever (allergic rhinitis/allergic rhino‐conjunctivitis) (<a href="./references#CD013682-bbs2-0093" title="HillDA , SpergelJM . The atopic march: critical evidence and clinical relevance. Annals of Allergy, Asthma &amp; Immunology2018;120(2):131–7. [DOI: 10.1016/j.anai.2017.10.037]">Hill 2018</a>). The main mechanistic features of the atopic march are thought to be epidermal barrier disruption, pathologically skewed T helper (Th)<sub>2</sub> immune responses, and chronic inflammation. This model has been challenged by cohort studies describing different disease trajectories (<a href="./references#CD013682-bbs2-0098" title="IlliS , vonMutiusE , LauS , NickelR , GrüberC , NiggemannB , et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. Journal of Allergy and Clinical Immunology2004;113(5):925–31. [DOI: 10.1016/j.jaci.2004.01.778]">Illi 2004</a>; <a href="./references#CD013682-bbs2-0120" title="PunekarYS , SheikhA . Establishing the sequential progression of multiple allergic diagnoses in a UK birth cohort using the general practice research database. Clinical &amp; Experimental Allergy2009;39(12):1889–95. [DOI: 10.1111/j.1365-2222.2009.03366.x]">Punekar 2009</a>; <a href="./references#CD013682-bbs2-0132" title="SimpsonA , TanVY , WinnJ , SvensénM , BishopCM , HeckermanDE , et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. American Journal of Respiratory and Critical Care Medicine2010;181(11):1200–6. [DOI: 10.1164/rccm.200907-1101OC]">Simpson 2010</a>), and more recently by the characterisation of distinct atopic dermatitis phenotypes, according to age of onset, presence of sensitisation to food and aero‐allergens, family history of atopic diseases and subsequent development of asthma or other atopic comorbidities (<a href="./references#CD013682-bbs2-0066" title="AmatF , Saint-PierreP , BourratE , NemniA , CoudercR , Boutmy-DeslandesE , et al. Early-onset atopic dermatitis in children: which are the phenotypes at risk of asthma? Results from the ORCA cohort. PLoS One2015;10(6):e0131369. [DOI: 10.1371/journal.pone.0131369]">Amat 2015</a>; <a href="./references#CD013682-bbs2-0125" title="RoduitC , FreiR , DepnerM , KarvonenAM , RenzH , Braun-FahrländerC , et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatrics2017;17(7):655–62. [DOI: 10.1001/jamapediatrics.2017.0556]">Roduit 2017</a>). </p> <p>Data from the Global Burden of Disease Study estimate that at least 6% of children aged between five and nine years old have a history of asthma; 3% of children aged between one and four years old have a history of urticaria, and 8% within the same age range have a history of atopic dermatitis (<a href="./references#CD013682-bbs2-0086" title="Global Burden of Disease Collaborative Network. Global Burden of Disease study 2017 (GBD 2017) results, 2018. ghdx.healthdata.org/gbd-results-tool (accessed 25 March 2020).">Global Burden of Disease 2018</a>). For urticaria, the estimated prevalence is at least 2.5 times higher in countries with high socioeconomic indices than in less economically developed countries (<a href="./references#CD013682-bbs2-0086" title="Global Burden of Disease Collaborative Network. Global Burden of Disease study 2017 (GBD 2017) results, 2018. ghdx.healthdata.org/gbd-results-tool (accessed 25 March 2020).">Global Burden of Disease 2018</a>). </p> <p>The prevalence of asthma has levelled off in countries with the most affluent economies; by contrast, it has continued to increase in low‐to middle‐income countries with increasing urbanisation and the adoption of a Western lifestyle (<a href="./references#CD013682-bbs2-0071" title="BousquetJ , BousquetPJ , GodardP , DauresJP . The public health implications of asthma. Bulletin of the World Health Organization2005;83(7):548–54. [PMID: 16175830]">Bousquet 2005</a>; <a href="./references#CD013682-bbs2-0094" title="HolgateST , WenzelS , PostmaDS , WeissST , RenzH , SlyPD . Asthma. Nature Reviews. Disease Primers2015;1:15025. [DOI: 10.1038/nrdp.2015.25]">Holgate 2015</a>). The true prevalence of IgE‐mediated food allergy, as well as its apparent increase, is difficult to determine using population‐based data (<a href="./references#CD013682-bbs2-0080" title="DunlopJH , KeetCA . Epidemiology of food allergy. Immunology and Allergy Clinics of North America2018;38(1):13–25. [PMID: 10.1016/j.iac.2017.09.002.]">Dunlop 2018</a>; <a href="./references#CD013682-bbs2-0110" title="National Academies of Sciences, Engineering, and Medicine. Finding a path to safety in food allergy: assessment of the global burden, causes, prevention, management, and public policy. Washington, DC: The National Academies Press 2017. [DOI: doi.org/10.17226/23658]">NAS 2017</a>). This is because a reproducible immune response following the consumption of the suspected food allergen, can only be assessed through a formal oral food challenge (<a href="./references#CD013682-bbs2-0080" title="DunlopJH , KeetCA . Epidemiology of food allergy. Immunology and Allergy Clinics of North America2018;38(1):13–25. [PMID: 10.1016/j.iac.2017.09.002.]">Dunlop 2018</a>). This medical procedure is expensive and time consuming, and as noted in a previous systematic review, over the last decade few epidemiological studies have used it to define IgE‐mediated food allergy in paediatric populations (<a href="./references#CD013682-bbs2-0113" title="NwaruBI , HicksteinL , PanesarSS , MuraroA , WerfelT , CardonaV , et al. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy2014;69(1):62-75. [DOI: 10.1111/all.12305]">Nwaru 2014</a>). In that regard, the estimated overall prevalence of challenge‐confirmed IgE‐mediated food allergy in Australia during the first year of life was 10.4% (95% confidence interval (CI) 9.3% to 11.5%; 9.0% for raw egg allergy, 95% CI 7.8% to 10.0%) (<a href="./references#CD013682-bbs2-0089" title="OsborneNJ , KoplinJJ , MartinPE , GurrinLC , LoweAJ , MathesonMC , et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. Journal of Allergy and Clinical Immunology2011;127(3):668–76.e1–2. [DOI: 10.1016/j.jaci.2011.01.039]">HealthNuts Study 2011</a>). On the other hand, findings from a large multinational birth cohort study carried out in Europe showed that the mean incidence of hen's egg allergy by two years old was estimated at 0.84%, (95% CI 0.67 to 1.03), and varied across countries with Greece reporting the lowest (0.07%; 95% CI 0.00 to 0.37%), and the UK the highest incidence (2.18%, 95% CI 1.27 to 3.47) (<a href="./references#CD013682-bbs2-0084" title="XepapadakiP , FiocchiA , GrabenhenrichL , RobertsG , GrimshawKE , FiandorA , et al. Incidence and natural history of hen's egg allergy in the first 2 years of life-the EuroPrevall birth cohort study. Allergy2016;71(3):350-7. [DOI: 10.1111/all.12801]">EuroPrevall 2016</a>). In this study, double‐blinded placebo‐controlled oral food challenges were carried out with pasteurised raw hen egg powder, which is reported by the authors as having an analogous allergenicity to raw egg (<a href="./references#CD013682-bbs2-0084" title="XepapadakiP , FiocchiA , GrabenhenrichL , RobertsG , GrimshawKE , FiandorA , et al. Incidence and natural history of hen's egg allergy in the first 2 years of life-the EuroPrevall birth cohort study. Allergy2016;71(3):350-7. [DOI: 10.1111/all.12801]">EuroPrevall 2016</a>).  </p> </section> <section id="CD013682-sec-0011"> <h3 class="title" id="CD013682-sec-0011">Description of the intervention</h3> <p>Whole‐cell pertussis‐ (whooping cough) containing vaccines (wP) are suspensions of killed <i>Bordetella</i> <i>pertussis</i> bacteria, the causative agent of pertussis. These vaccines were introduced in the 1940s and implemented by the World Health Organization (WHO) in 1974 for the primary prevention of pertussis through the 'Expanded Programme on Immunization' (EPI) (<a href="./references#CD013682-bbs2-0099" title="KejaK , ChanC , HaydenG , HendersonRH . Expanded programme on immunization. World Health Statistics Quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales1988;41(2):59–63. [PMID: 3176515]">Keja 1988</a>). By 2015, 64% of countries worldwide had wP‐based national immunisation schedules (<a href="./references#CD013682-bbs2-0144" title="World Health Organization. Pertussis vaccine position paper. Whole cell pertussis vaccines: summary of evidence relevant to schedules. www.who.int/immunization/sage/meetings/2015/april/2_wP_summary_WG_23Mar2015_submitted.pdf?ua= (accessed 13 July 2020).">WHO 2015</a>). wP vaccines are safe and mainly available as a multivalent co‐formulation with diphtheria (D) and tetanus (T) toxoids, <i>Haemophilus</i> <i>influenzae</i> type b (Hib) and hepatitis B (HepB) antigens (<a href="./references#CD013682-bbs2-0145" title="World Health Organization. Pertussis vaccines: WHO position paper – September 2015. Weekly Epidemiological Record2015;90(35):433–58. [PMID: 26320265]">WHO 2015a</a>). This combination vaccine is available in 73 of the lowest‐income economies via the support of Gavi, the Vaccine Alliance (<a href="./references#CD013682-bbs2-0085" title="Gavi, the Vaccine Alliance. Pentavalent vaccine support. www.gavi.org/types-support/vaccine-support/pentavalent (accessed 11 March 2020).">Gavi 2020</a>), as well as in self‐financed lower‐middle income countries non‐eligible for Gavi's funding programmes (<a href="./references#CD013682-bbs2-0138" title="United Nations Children's Fund Supply Division. Pentavalent vaccine (DTwP-HepB-Hib): market and supply update. www.unicef.org/supply/reports/pentavalent-vaccinedtwp-hepb-hib-market-and-supply-update (accessed 13 July 2020).">UNICEF 2017</a>). The inception of Gavi's support for wP‐based '5‐in‐1' (pentavalent) formulations commenced in 2001 and by the end of 2018, at least 467 million children living in eligible countries had been vaccinated (<a href="./references#CD013682-bbs2-0085" title="Gavi, the Vaccine Alliance. Pentavalent vaccine support. www.gavi.org/types-support/vaccine-support/pentavalent (accessed 11 March 2020).">Gavi 2020</a>). This has contributed to the marked reduction in the global burden of pertussis and pertussis‐related deaths (<a href="./references#CD013682-bbs2-0074" title="ChowMY , KhandakerG , McIntyreP . Global childhood deaths from pertussis: a historical review. Clinical Infectious Diseases2016;63 Suppl 4:S134–41. [DOI: 10.1093/cid/ciw529]">Chow 2016</a>), and has had accompanying economic and social benefits. </p> <p>Fever, irritability and local injection site reactions (such as pain, redness and swelling) are expected adverse events that arise following immunisation with wP‐based vaccines. Although these events are self‐limiting, the development of less reactogenic subunit acellular pertussis‐containing vaccines (aP) in the 1970s (<a href="./references#CD013682-bbs2-0128" title="SatoY , KimuraM , FukumiH . Development of a pertussis component vaccine in Japan. Lancet1984;1(8369):122–6. [PMID: 6140441]">Sato 1984</a>), instigated a changeover from wP‐ to aP‐based schedules in high‐income countries from the 1980s to the early 2000s. </p> <p>The tolerability profile of aP versus wP has been reviewed systematically elsewhere and favours aP formulations (<a href="./references#CD013682-bbs2-0116" title="PattersonJ , KaginaBM , GoldM , HusseyGD , MuloiwaR . Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine2018;36(40):6007–16. [DOI: 10.1016/j.vaccine.2018.08.022]">Patterson 2018</a>; <a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a>); nonetheless, priming with wP is safe, and may result in longer lasting protection against pertussis than priming with aP vaccines (<a href="./references#CD013682-bbs2-0073" title="Centers for Disease Control and Prevention (CDC). Pertussis epidemic – Washington, 2012. MMWR. Morbidity and Mortality Weekly Report2012;61(28):517–22. [PMID: 22810264]">CDC 2012</a>; <a href="./references#CD013682-bbs2-0103" title="LikoJ , RobisonSG , CieslakPR . Priming with whole-cell versus acellular pertussis vaccine. New England Journal of Medicine2013;368(6):581–2. [DOI: 10.1056/NEJMc1212006]">Liko 2013</a>; <a href="./references#CD013682-bbs2-0131" title="SheridanSL , WareRS , GrimwoodK , LambertSB . Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA2012;308(5):454–6. [DOI: 10.1001/jama.2012.6364]">Sheridan 2012</a>; <a href="./references#CD013682-bbs2-0139" title="van derLeeS , HendrikxLH , SandersEA , BerbersGA , Buisman A-M. Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles. Frontiers in Immunology2018;9:51. [DOI: 10.3389/fimmu.2018.00051]">van der Lee 2018</a>). A potential causal relationship between wP and rare neurological outcomes (i.e. encephalopathy) was proposed, but could not be confirmed by detailed examination in the UK National Childhood Encephalopathy Study (<a href="./references#CD013682-bbs2-0107" title="MillerD , MadgeN , DiamondJ , WadsworthJ , RossE . Pertussis immunisation and serious acute neurological illnesses in children. BMJ1993;307(6913):1171–6. [DOI: 10.1136/bmj.307.6913.1171]">Miller 1993</a>), as well as other epidemiological and genomic analyses (<a href="./references#CD013682-bbs2-0070" title="BerkovicSF , HarkinL , McMahonJM , PelekanosJT , ZuberiSM , WirrellEC , et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurology2006;5(6):488–92. [DOI: 10.1016/S1474-4422(06)70446-X]">Berkovic 2006</a>; <a href="./references#CD013682-bbs2-0106" title="McIntoshAM , McMahonJ , DibbensLM , IonaX , MulleyJC , SchefferIE , et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurology2010;9(6):592–8. [DOI: 10.1016/S1474-4422(10)70107-1]">McIntosh 2010</a>; <a href="./references#CD013682-bbs2-0122" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768–73. [PMID: 16940831]">Ray 2006</a>). The WHO have advised that countries using wP should continue using wP‐based primary vaccination courses (<a href="./references#CD013682-bbs2-0145" title="World Health Organization. Pertussis vaccines: WHO position paper – September 2015. Weekly Epidemiological Record2015;90(35):433–58. [PMID: 26320265]">WHO 2015a</a>). </p> </section> <section id="CD013682-sec-0012"> <h3 class="title" id="CD013682-sec-0012">How the intervention might work</h3> <p>During the neonatal and early infancy periods, a diversity of stimuli, including infections and vaccines, might determine future functional adaptations of the immune system (<a href="./references#CD013682-bbs2-0114" title="OlinA , HenckelE , ChenY , LakshmikanthT , PouC , MikesJ , et al. Stereotypic immune system development in newborn children. Cell2018;174(5):1277–92.e14. [DOI: 10.1016/j.cell.2018.06.045]">Olin 2018</a>). In that regard, differential immune profiles elicited by <i>B.</i> <i>pertussis</i> and pertussis‐containing vaccines have been described in human (<a href="./references#CD013682-bbs2-0079" title="deGraafH , IbrahimM , HillAR , GbesemeteD , VaughanAT , GorringeA , et al. Controlled human infection with Bordetella pertussis induces asymptomatic, immunising colonisation. Clinical Infectious Diseases2020;71(2):403–11. [DOI: 10.1093/cid/ciz840]">de Graaf 2020</a>), non‐human primate (<a href="./references#CD013682-bbs2-0142" title="WarfelJM , ZimmermanLI , Merkel, TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America2014;111(2):787–92. [DOI: 10.1073/pnas.1314688110]">Warfel 2014</a>), and other animal models (<a href="./references#CD013682-bbs2-0108" title="MillsKH , RyanM , RyanE , MahonBP . A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infection and Immunity1998;66(2):594–602. [PMID: 9453614]">Mills 1998</a>). </p> <p>Priming with aP vaccines induces Th<sub>2</sub>‐dominated immune responses (<a href="./references#CD013682-bbs2-0067" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [PMID: 9169747]">Ausiello 1997</a>; <a href="./references#CD013682-bbs2-0126" title="RoweJ , MacaubasC , MongerTM , HoltBJ , HarveyJ , PoolmanJT , et al. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infection and Immunity2000;68(7):3873–7. [DOI: 10.1128/iai.68.7.3873-3877.2000]">Rowe 2000</a>), with transient enhanced production of diphtheria, tetanus toxoid and pertussis toxin IgE (<a href="./references#CD013682-bbs2-0065" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]">Aalberse 2019</a>; <a href="./references#CD013682-bbs2-0090" title="HedenskogS , BjörksténB , BlennowM , GranströmG , GranströmM . Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. International Archives of Allergy and Applied Immunology1989;89(2-3):156–61. [DOI: 10.1159/000234939]">Hedenskog 1989</a>; <a href="./references#CD013682-bbs2-0095" title="HoltPG , SnellingT , WhiteOJ , SlyPD , DeKlerkN , CarapetisJ , et al. Transiently increased IgE responses in infants and pre-schoolers receiving only acellular Diphtheria-Pertussis-Tetanus (DTaP) vaccines compared to those initially receiving at least one dose of cellular vaccine (DTwP) – immunological curiosity or canary in the mine?Vaccine2016;34(35):4257–62. [DOI: 0.1016/j.vaccine.2016.05.048]">Holt 2016</a>). Furthermore, Th<sub>2</sub>‐skewed responses observed with aP vaccines appear to extend beyond vaccine antigens, as evidenced by a transiently increased egg‐ and milk‐specific IgE in early infancy (<a href="./references#CD013682-bbs2-0095" title="HoltPG , SnellingT , WhiteOJ , SlyPD , DeKlerkN , CarapetisJ , et al. Transiently increased IgE responses in infants and pre-schoolers receiving only acellular Diphtheria-Pertussis-Tetanus (DTaP) vaccines compared to those initially receiving at least one dose of cellular vaccine (DTwP) – immunological curiosity or canary in the mine?Vaccine2016;34(35):4257–62. [DOI: 0.1016/j.vaccine.2016.05.048]">Holt 2016</a>), as well as the induction of type 2 cytokines to the food antigen beta‐lactoglobulin at six months old (<a href="./references#CD013682-bbs2-0104" title="MascartF , HainautM , PeltierA , VerscheureV , LevyJ , LochtC . Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine2007;25(2):391–8. [DOI: 10.1016/j.vaccine.2006.06.046]">Mascart 2007</a>). In contrast, infection with <i>Bordetella</i> <i>pertussis</i> and wP vaccines induce Th<sub>1</sub>/Th<sub>17</sub> polarisation with minimal expression of type 2 immunity (<a href="./references#CD013682-bbs2-0067" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [PMID: 9169747]">Ausiello 1997</a>; <a href="./references#CD013682-bbs2-0092" title="HiggsR , HigginsSC , RossPJ , MillsKH . Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunology2012;5(5):485–500. [DOI: 10.1038/mi.2012.54]">Higgs 2012</a>; <a href="./references#CD013682-bbs2-0104" title="MascartF , HainautM , PeltierA , VerscheureV , LevyJ , LochtC . Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine2007;25(2):391–8. [DOI: 10.1016/j.vaccine.2006.06.046]">Mascart 2007</a>; <a href="./references#CD013682-bbs2-0142" title="WarfelJM , ZimmermanLI , Merkel, TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America2014;111(2):787–92. [DOI: 10.1073/pnas.1314688110]">Warfel 2014</a>). This effect has been hypothesised to facilitate the healthy transition from the Th<sub>2</sub>‐dominant immunophenotype seen in early infancy, to a more balanced Th<sub>1</sub>/Th<sub>17</sub>/Th<sub>2</sub> immunophenotype that may be necessary for the development of oral tolerance to foods, and allergy protective immune responses (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>). Therefore, vaccine schedules using wP as the first infant pertussis vaccine might overcome the persistent Th<sub>2</sub>‐skewed immunophenotype observed in some infants (<a href="https://revman.cochrane.org/417439426688068315" target="_blank">Holt 2016</a>), and thereby protect against IgE‐mediated food allergy and other atopic outcomes. </p> <p>Although mechanistic studies have found a propensity to type 1 T‐cell differentiation and possible development of an 'allergy protective immunophenotype' following early priming with wP (<a href="./references#CD013682-bbs2-0067" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [PMID: 9169747]">Ausiello 1997</a>; <a href="./references#CD013682-bbs2-0104" title="MascartF , HainautM , PeltierA , VerscheureV , LevyJ , LochtC . Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine2007;25(2):391–8. [DOI: 10.1016/j.vaccine.2006.06.046]">Mascart 2007</a>), three studies found no association between the type of pertussis vaccine received and subsequent risk of atopic diseases among European (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>), and Australian children (<a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>). </p> </section> <section id="CD013682-sec-0013"> <h3 class="title" id="CD013682-sec-0013">Why it is important to do this review</h3> <p>Allergic diseases have a significant economic, healthcare and quality‐of‐life impact. To date, the timely introduction of peanut and egg into the infant diet are the only evidence‐based prevention approaches against egg and peanut allergy (<a href="./references#CD013682-bbs2-0097" title="IerodiakonouD , Garcia-LarsenV , LoganA , GroomeA , CunhaS , ChivingeJ , et al. Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA2016;316(11):1181–92. [DOI: 10.1001/jama.2016.12623]">Ierodiakonou 2016</a>), and therefore, it is imperative to identify additional measures to avoid food sensitisation, and further development of food allergic reactions. Systematic reviews on the safety of pertussis‐containing vaccines have not addressed whether wP plays a role in the protection against food allergy or other atopic outcomes (<a href="./references#CD013682-bbs2-0116" title="PattersonJ , KaginaBM , GoldM , HusseyGD , MuloiwaR . Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine2018;36(40):6007–16. [DOI: 10.1016/j.vaccine.2018.08.022]">Patterson 2018</a>; <a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a>). Therefore, this review will provide a critical appraisal of the relevant evidence as well as directions for the future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013682-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013682-sec-0014"></div> <p>To assess the efficacy and safety of wP vaccinations in comparison to aP vaccinations in early infancy for the prevention of atopic diseases in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013682-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013682-sec-0015"></div> <section id="CD013682-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013682-sec-0017"> <h4 class="title">Types of studies</h4> <p>Eligibility was restricted to studies with at least six months of follow‐up and the following designs, irrespective of publication status, date of publication, publication type or language. </p> <p> <ol id="CD013682-list-0001"> <li> <p>Randomised controlled trials (RCTs) and cluster‐RCTs.</p> </li> <li> <p>Controlled clinical trials (CCTs) or trials in which it was not clearly stated that the intervention or comparison was allocated at random, but in which it is not possible to exclude randomisation (<a href="./references#CD013682-bbs2-0100" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al, on behalf of the Cochrane Information Retrieval Methods Group. Technical supplement to chapter 4: searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021a</a>). We classified quasi‐randomised studies as CCTs. </p> </li> <li> <p>For atopic outcomes, we assessed case‐control and cohort studies (hereafter referred as non‐randomised studies of interventions (NRSIs)) in which the individual vaccine status of the child was known. </p> </li> </ol> </p> <p>We did not include cross‐over trials since any differential immunological effects induced by pertussis vaccination are likely to be long term, and may still be patent in adulthood, irrespective of subsequent booster doses of aP during or after adolescence (<a href="./references#CD013682-bbs2-0069" title="BancroftT , DillonMB , da Silva AntunesR , PaulS , PetersB , CrottyS , et al. Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cellular Immunology2016;304-305:35–43. [DOI: 10.1016/j.cellimm.2016.05.002]">Bancroft 2016</a>; <a href="./references#CD013682-bbs2-0077" title="da Silva AntunesR , BaborM , CarpenterC , KhalilN , CorteseM , MentzerAJ , et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. Journal of Clinical Investigation2018;128(9):3853–65. [DOI: 10.1172/JCI121309]">da Silva Antunes 2018</a>). </p> </section> <section id="CD013682-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children aged less than 18 years old, who received their first dose of wP‐ or aP‐containing vaccines before the age of six months, irrespective of any subsequent pertussis vaccinations (wP, aP or none). </p> </section> <section id="CD013682-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies where:</p> <p> <ol id="CD013682-list-0002"> <li> <p>the experimental intervention was vaccination with any vaccine formulation that contained wP; </p> </li> <li> <p>the comparator was vaccination with any vaccine formulation that contained aP.</p> </li> </ol> </p> <p>Placebo vaccination or no intervention were not accepted as comparators, as they do not represent the standard of care for the primary prevention of pertussis. </p> <p>The first dose of the wP‐ or aP‐containing vaccines was required to have been administered before participants reached six months old, irrespective of any subsequent vaccinations. This is because early infancy is thought to be the critical period for maturation from a Th<sub>2</sub>‐dominant to a balanced Th<sub>1</sub>/Th<sub>2</sub>/Th<sub>17</sub> immunophenotype, and therefore, where immunisation might affect this process. Booster dose studies were only eligible if they met the following criteria: </p> <p> <ol id="CD013682-list-0003"> <li> <p>the comparison was between recipients of one or more doses of wP versus aP;</p> </li> <li> <p>children received a randomly allocated first dose of wP or aP before six months of age; </p> </li> <li> <p>information on the type of first dose of pertussis‐containing vaccine was available.</p> </li> </ol> </p> <p>We accepted co‐administered vaccines in either the experimental and control group. Matching between groups was not required for randomised studies; for NRSIs, we assessed co‐interventions as recommended by the ROBINS‐I tool (<a href="./references#CD013682-bbs2-0134" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [DOI: 10.1136/bmj.i4919 ]">Sterne 2016a</a>). </p> </section> <section id="CD013682-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the outcomes listed below. Studies that did not assess any of the outcomes of interest were excluded. </p> <section id="CD013682-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013682-list-0004"> <li> <p>Diagnosis of IgE‐mediated food allergy.</p> </li> <li> <p>Cumulative incidence of atopic diseases. As planned and prespecified in our protocol (Data Synthesis section), we added this outcome as only one study systematically assessed the atopic outcomes of interest, and 'diagnosis of IgE‐mediated food allergy' outcome data were not available by study arm. </p> </li> <li> <p>All‐cause serious adverse events (SAEs) following immunisation with wP or aP (safety). This outcome was defined as any adverse event that resulted in death, was life‐threatening, required hospitalisation or prolongation of existing hospitalisation, or resulted in persistent or significant disability or incapacity (<a href="./references#CD013682-bbs2-0096" title="International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231–4. [PMID: 11656783]">ICH 1997</a>). Because this standard definition has not been universally applied in trials until recently, we also accepted adverse events that met the above‐mentioned criteria, irrespective of whether the report refers to <a href="./references#CD013682-bbs2-0096" title="International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231–4. [PMID: 11656783]">ICH 1997</a>. The following outcome domains were extracted from the definition and included in the review: </p> <ol id="CD013682-list-0005"> <li> <p>death (all‐cause mortality);</p> </li> <li> <p>events leading to admission to hospital;</p> </li> <li> <p>events described as 'life‐threatening';</p> </li> <li> <p>events leading to persistent or significant disability or incapacity.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD013682-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013682-list-0006"> <li> <p>Diagnosis of anaphylaxis (not vaccine‐associated).</p> </li> <li> <p>Diagnosis of asthma.</p> </li> <li> <p>Diagnosis of allergic rhinitis or allergic rhino‐conjunctivitis.</p> </li> <li> <p>Diagnosis of eczema or atopic dermatitis.</p> </li> <li> <p>Diagnosis of urticaria (not vaccine‐associated).</p> </li> <li> <p>Diagnosis of encephalopathy (safety).</p> </li> </ol> </p> <p>Primary and secondary atopic outcomes could be diagnosed at any point after enrolment by any of the following (any item listed under number 1 +/‐ any item listed under number 2 or where applicable, any item listed under number 3): </p> <p> <ol id="CD013682-list-0007"> <li> <p>a positive history of that outcome ascertained via:</p> <ol id="CD013682-list-0008"> <li> <p>parental report (whether using validated questionnaires or not);</p> </li> <li> <p>clinician diagnosis;</p> </li> <li> <p>parental report and clinician diagnosis;</p> </li> </ol> </li> <li> <p>evidence of IgE‐mediated sensitisation via:</p> <ol id="CD013682-list-0009"> <li> <p>a positive skin prick test;</p> </li> <li> <p>elevated total or specific elevated IgE;</p> </li> </ol> </li> <li> <p>one or both (where applicable) of:</p> <ol id="CD013682-list-0010"> <li> <p>evidence of a formal positive oral food challenge to the implicated food;</p> </li> <li> <p>confirmed expiratory airflow limitation (i.e. spirometrically confirmed asthma).</p> </li> </ol> </li> </ol> </p> <p>If eligible studies reported atopic outcomes using more than one method, we used the following hierarchy of diagnoses: clinician‐diagnosed allergic disease <i>with</i> evidence of IgE‐mediated sensitisation, over clinician diagnosis <i>without</i> confirmed IgE‐mediated sensitisation. However, clinician diagnosis without confirmed IgE‐mediated sensitisation was used over parental report using validated questionnaires or not. Where applicable, we used formal challenge confirmed IgE‐mediated food allergy or evidence of variable expiratory airflow limitation over clinician‐diagnosed allergic disease with evidence of IgE‐mediated sensitisation. </p> <p>As the efficacy of wP and aP for preventing pertussis has been summarised by a Cochrane Review (<a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a>), and solicited systemic and local adverse events have been reviewed separately (<a href="./references#CD013682-bbs2-0116" title="PattersonJ , KaginaBM , GoldM , HusseyGD , MuloiwaR . Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine2018;36(40):6007–16. [DOI: 10.1016/j.vaccine.2018.08.022]">Patterson 2018</a>), these were not included as outcomes. </p> </section> </section> </section> <section id="CD013682-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted systematic searches following the recommendations provided in Chapter 4/Technical Supplement (<a href="./references#CD013682-bbs2-0100" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al, on behalf of the Cochrane Information Retrieval Methods Group. Technical supplement to chapter 4: searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021a</a>; <a href="./references#CD013682-bbs2-0101" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021b</a>) and Chapter 24 (<a href="./references#CD013682-bbs2-0123" title="ReevesBC , DeeksJJ , HigginsJP , SheaB , TugwellP , WellsGA , on behalf of the Cochrane Non-Randomized Studies of Interventions Methods Group. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Reeves 2021</a>) of the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> <i>of</i> <i>Interventions</i> for the identification and selection of eligible studies. There were no language restrictions, but the electronic searches were limited from 1970 to present, as aP vaccines were developed in the late 1970s, and used for the first time in Japan for mass‐immunisation in 1981 (<a href="./references#CD013682-bbs2-0128" title="SatoY , KimuraM , FukumiH . Development of a pertussis component vaccine in Japan. Lancet1984;1(8369):122–6. [PMID: 6140441]">Sato 1984</a>). The date of the search was 7 September 2020. </p> <p>To maximise the sensitivity of the search strategies for the identification of controlled NRSIs, we applied a filter to the electronic searches in Ovid MEDLINE and Embase. This filter was developed by <a href="./references#CD013682-bbs2-0141" title="WaffenschmidtS , Navarro-RuanT , HobsonN , HausnerE , SauerlandS , HaynesRB . Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE. Research Synthesis Methods2020;11(5):617–26. [DOI: 10.1002/jrsm.1425]">Waffenschmidt 2020</a>, and at the time of the search had only been validated for Ovid MEDLINE and Pubmed. </p> <section id="CD013682-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ol id="CD013682-list-0011"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, issue 9; searched via the Cochrane Register of Studies Web): we modified the CENTRAL search strategy of <a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a> by using free‐text words for subject‐specific aspects and by incorporating the study population into the search fields (<a href="./appendices#CD013682-sec-0137">Appendix 2</a>). This strategy was adapted for the searches of other electronic databases. </p> </li> <li> <p>Ovid MEDLINE (R) All (<a href="./appendices#CD013682-sec-0138">Appendix 3</a>). </p> </li> <li> <p>Embase (<a href="./appendices#CD013682-sec-0139">Appendix 4</a>). </p> </li> </ol> </p> </section> <section id="CD013682-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the following resources from inception to 7 September 2020 (<a href="./appendices#CD013682-sec-0140">Appendix 5</a>): </p> <p> <ul id="CD013682-list-0012"> <li> <p>US National Library of Medicine's trial registry (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) portal (<a href="https://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal" target="_blank">www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal</a>). </p> </li> <li> <p>US Food and Drug Administration (<a href="https://www.fda.gov/" target="_blank">www.fda.gov/</a>). </p> </li> <li> <p>European Medicines Agency (<a href="https://www.ema.europa.eu/en" target="_blank">www.ema.europa.eu/en</a>). </p> </li> <li> <p>Pharmaceutical companies: GSK trial registry (<a href="https://www.gsk-studyregister.com/en/" target="_blank">www.gsk-studyregister.com/en/</a>), Sanofi (<a href="https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pasteur#para_4" target="_blank">www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pasteur#para_4</a>), and Pfizer (<a href="https://www.pfizer.com/" target="_blank">www.pfizer.com/</a>) websites. </p> </li> <li> <p>Reference list and citations of eligible studies.</p> </li> <li> <p>Additional grey literature (Open Grey; <a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013682-sec-0026"> <h3 class="title" id="CD013682-sec-0026">Data collection and analysis</h3> <section id="CD013682-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GPC and JR) independently screened the titles and abstracts of search results against the prespecified eligibility criteria (see <a href="#CD013682-sec-0016">Criteria for considering studies for this review</a>). Disagreements were resolved through discussion with a third review author (TS). For potentially eligible references or where eligibility was unclear, we retrieved the full‐text reports. </p> <p>Two review authors (GPC and JR) independently appraised the full‐text reports against the eligibility criteria. Similarly, disagreements were resolved through discussion with a third review author (of MJE and TS). We documented the selection process, and where applicable, collated multiple references of studies under the same identifier (so that the study, rather than the reference, was the unit of interest). Where a booster dose study enrolled children primed with wP or aP in a single RCT (i.e. a single cohort), we linked it to the primary series trial. However, if the  population of a booster dose study included children from different cohorts, the booster dose study was presented separately. </p> </section> <section id="CD013682-sec-0028"> <h4 class="title">Data extraction and management</h4> <section id="CD013682-sec-0029"> <h5 class="title">Randomised controlled trials</h5> <p>Two review authors (GPC and JR) independently extracted data from the eligible studies using a customised data collection form, following the recommendations provided in Chapter 5 of the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> <i>of</i> <i>Interventions</i> (<a href="./references#CD013682-bbs2-0102" title="LiT , HigginsJP , DeeksJJ . Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Li 2021</a>). We resolved discrepancies through discussion or through the arbitration of a third review author (of MJE and TS). Where available, we extracted the following information and where required, we attempted to contact authors of the original reports for clarification or to request missing data. </p> <p> <ol id="CD013682-list-0013"> <li> <p>Initials of data extractors, date of data extraction and citation.</p> </li> <li> <p>Study characteristics: study design, recruitment and sampling procedures, start and end dates of the trial, and length of follow‐up. </p> </li> <li> <p>Population (P): study setting and country and World Bank income level of country, ethnicity, eligibility criteria, unit of analysis, number of children in each study group, withdrawals/loss to follow‐up, mean age, age range, sex, and comorbidities (if any). </p> </li> <li> <p>Intervention (I) and comparator (C): type of pertussis‐containing vaccine administered (generic name), manufacturer, route of delivery, dose, and schedule. </p> </li> <li> <p>Vaccines co‐administered: generic name, manufacturer, route of delivery, dose, and schedule. </p> </li> <li> <p>Vaccination with Bacille‐Calmette‐Guérin (BCG or vaccine against tuberculosis): manufacturer and dose timing. </p> </li> <li> <p>Antipyretic/analgesic use.</p> </li> <li> <p>Outcomes (O): primary and secondary outcomes and their definition, evidence of assessment and whether they were collected systematically, time points reported and method of aggregation. </p> </li> <li> <p>Risk of bias (<a href="#CD013682-sec-0031">Assessment of risk of bias in included studies</a>). </p> </li> <li> <p>Source(s) of funding.</p> </li> <li> <p>Authors' conflicts of interest.</p> </li> <li> <p>Miscellaneous: correspondence required, comments from the reviewers or study authors.</p> </li> </ol> </p> <p>The data extracted on population, intervention, comparison and outcomes were used to systematically grade the directness of the evidence. This was described in the protocol of this review as "judgement of directness of each one of the PICO elements using <a href="./references#CD013682-bbs2-0129" title="SchünemannHJ , TugwellP , ReevesBC , AklEA , SantessoN , SpencerFA , et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Research Synthesis Methods2013;4:49–62. [DOI: 10.1002/jrsm.1078 ]">Schünemann 2013</a> checklist" (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>).  </p> </section> <section id="CD013682-sec-0030"> <h5 class="title">Non‐randomised studies of interventions</h5> <p>For NRSIs, we extracted the information as for RCTs, as well as potential confounding factors (and any attempt to adjust for these). MJE, PR, PH and TS were not involved in any step regarding the assessment of their case‐control study (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>). </p> </section> </section> <section id="CD013682-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD013682-sec-0032"> <h5 class="title">Randomised controlled trials</h5> <p>Two review authors (GPC and JR) independently assessed the risk of bias using Cochrane's 'Risk of bias' tool version 1, following the guidance set out in the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> <i>of</i> <i>Interventions</i> to evaluate the appropriate domains (<a href="./references#CD013682-bbs2-0091" title="HigginsJP , AltmanDG , SterneJA . Chapter 8:  Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org2011.">Higgins 2011</a>). These are sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome data, and selective reporting, as well as other sources of bias (<a href="./references#CD013682-bbs2-0091" title="HigginsJP , AltmanDG , SterneJA . Chapter 8:  Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org2011.">Higgins 2011</a>). In this case, each domain was assessed as having low, unclear or high risk of bias. We resolved disagreements by discussion and where required, through the arbitration of a third review author (of MJE, CBJ, PR, PH or TS). </p> </section> <section id="CD013682-sec-0033"> <h5 class="title">Non‐randomised studies of interventions</h5> <p>Two review authors (GPC and JR) independently assessed the risk of bias using the ROBINS‐I tool (version 1, August 2016; <a href="./references#CD013682-bbs2-0134" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [DOI: 10.1136/bmj.i4919 ]">Sterne 2016a</a>), following the tool's detailed guidance (<a href="./references#CD013682-bbs2-0135" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info [accessed before April 2021].">Sterne 2016b</a>), the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> <i>of</i> <i>Interventions</i> (<a href="./references#CD013682-bbs2-0136" title="SterneJA , HernánMA , McAleenanA , ReevesBC , HigginsJP . Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Sterne 2021</a>), the author guidance (<a href="./references#CD013682-bbs2-0075" title="Cochrane Methods. Risk Of Bias In Non-Randomized Studies - of Interventions (ROBINS-I). ROBINS-I Resources and Reporting Guidance2020:1-14.">Cochrane Methods 2020</a>), and the target trial methodology<i>.</i> The outcomes assessed were: diagnosis of IgE‐mediated food allergy, diagnosis of anaphylaxis (not vaccine‐associated) and diagnosis of asthma. We judged the bias arising pre‐intervention (bias due to confounding and the process of selection of children in the study); at‐intervention (bias in classification of interventions) and post‐intervention domains (bias due to deviations from intended interventions, due to missing data, in measurement of the outcome and in selection of the reported result), by answering 'signalling questions' with further risk of bias judgement, guided by the tool algorithms. We resolved disagreements through discussion, and where required, through the arbitration of a third review author (TS). Judgements were documented in free‐text boxes and incorporated into the ROBINS‐I tables; no further tools (i.e. computer programmes) were used to manage these assessments. </p> <p>In our protocol (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>), we noted the following confounders: year of birth, birth order, family history of allergic diseases, socioeconomic status, vaccination with BCG, prematurity and breastfeeding status. BCG meets the definition of co‐intervention specified in the detailed guidance of the ROBINS‐I tool, and therefore, we used this term in the risk of bias assessments. We also considered whether the study involved unmatched co‐administration of vaccines between groups.  </p> <p>We classified the overall risk of bias judgement for a specific outcome within each NRSI as: low risk of bias (if we judged all the domains at low risk of bias); moderate risk of bias (if we judged all the domains at low or moderate risk of bias, and the study provided good‐quality evidence for an RCT, but not comparable to a well‐conducted RCT); serious risk of bias (if we judged at least one domain at serious risk of bias, but no domain as having a critical risk of bias); critical risk of bias (if we judged at least one domain at critical risk of bias) or no information (if data were insufficient and a judgement could not be made) (<a href="./references#CD013682-bbs2-0134" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919. [DOI: 10.1136/bmj.i4919 ]">Sterne 2016a</a>). </p> </section> </section> <section id="CD013682-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised and reported the number and proportion of children who experienced primary and secondary outcomes at least once (rather than as a count of outcomes per child). For each outcome, we quantified the effect of wP versus aP as a ratio of the risk (using risk ratios (RRs) and 95% CIs) or ratio of the odds for case‐control studies (odds ratio (ORs) and 95% CIs).  </p> </section> <section id="CD013682-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>If a study had multiple comparison groups, we omitted any groups that did not meet our inclusion criteria, but listed them in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. Where appropriate, we used one of the following strategies: </p> <p> <ol id="CD013682-list-0014"> <li> <p>where more than one relevant group was reported, we combined them to create a single pairwise comparison or; </p> </li> <li> <p>we included the intervention groups separately in the analysis and split the control group. </p> </li> </ol> </p> </section> <section id="CD013682-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data as advised in Chapter 10 of the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> (<a href="./references#CD013682-bbs2-0078" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>); where possible, we analysed primary and secondary outcomes as intention‐to‐treat (randomised studies). Irrespective of study design, we attempted to contact the study investigators or sponsors to obtain missing outcome data. If the report presented the outcome data in a figure and the raw values were not described or not feasible to obtain from the investigators of the study, we extracted the relevant information from a screenshot of the figure of interest using a web‐based data extraction tool (<a href="https://revman.cochrane.org/423619948848611473" target="_blank">WebPlotDigitizer 2020</a>). </p> </section> <section id="CD013682-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed the data in RCTs and NRSIs separately. We examined the clinical and methodological diversity between studies and used this information to decide whether studies were similar enough to be pooled meaningfully. The presence of statistical heterogeneity of intervention effects across studies included in meta‐analyses was assessed by inspecting the point estimates and CIs of forest plots. We assessed the results of the Chi<sup>2</sup> test for each meta‐analysis (with significance at the 0.1 level) and quantified heterogeneity using the I<sup>2</sup> statistic. We used the thresholds recommended in Chapter 10 of the <i>Cochrane</i> <i>Handbook</i> <i>of</i> <i>Systematic</i> <i>Reviews</i> <i>of</i> <i>Interventions</i> (<a href="./references#CD013682-bbs2-0078" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>), with considerable heterogeneity defined as an I<sup>2</sup> greater than 75%. </p> <p>We investigated potential causes of any detected heterogeneity through the analyses described in <a href="#CD013682-sec-0045">Sensitivity analysis</a> below. </p> </section> <section id="CD013682-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>Where 10 or more studies were included in a meta‐analysis (see <a href="#CD013682-sec-0039">Data synthesis</a>), we used contour‐enhanced funnel plots to distinguish non‐reporting bias from other sources of asymmetry (<a href="./references#CD013682-bbs2-0115" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Page 2021</a>; <a href="./references#CD013682-bbs2-0118" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991–6. [PMID: 18538991]">Peters 2008</a>). These plots were generated in R using the 'metafor' package (<a href="./references#CD013682-bbs2-0121" title="R: A language and environment for statistical computing. Version 4.0.2. Vienna, Austria: R Foundation for Statistical Computing, 2020. Available at www.R-project.org.">R</a>; <a href="./references#CD013682-bbs2-0140" title="Viechtbauer, W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software2010;36(3):1–48.">Viechtbauer 2010</a>). </p> </section> <section id="CD013682-sec-0039"> <h4 class="title">Data synthesis</h4> <section id="CD013682-sec-0040"> <h5 class="title">IgE‐mediated food allergy and other atopic outcomes</h5> <section id="CD013682-sec-0041"> <h6 class="title">Randomised controlled trials</h6> <p>Only one study systematically assessed the atopic outcomes of interest (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>). Since IgE‐mediated food allergy was not reported by study arm, we extracted data on a broader outcome domain (i.e. cumulative incidence of atopic disease), as prespecified in our protocol (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>). The source of information was a bar plot, and we used <a href="./references#CD013682-bbs2-0143" title="WebPlotDigitizer. Version 4.4. Rohatgi A, 2020. Available at automeris.io/WebPlotDigitizer.">WebPlotDigitizer 2020</a> to obtain the raw numbers. Analogous methods were implemented to obtain the relevant data points for asthma and atopic dermatitis. </p> <p>We carried out narrative synthesis following the protocol of this review, and the <i>SWiM</i> <i>Reporting</i> <i>Guideline</i> (<a href="./references#CD013682-bbs2-0072" title="CampbellM , McKenzieJE , SowdenA , KatikireddiSV , BrennanSE , EllisS , et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ2020;368:l6890. [DOI: 10.1136/bmj.l6890]">Campbell 2020</a>). We used RRs with 95% CIs as the standard metric. Data were pooled using random‐effects inverse‐variance method. This study is presented in forest plots generated in <a href="./references#CD013682-bbs2-0124" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web</a> suppressing the summary estimate. Additional details are described in the <a href="#CD013682-sec-0103">Effects of interventions</a> section based on GRADE (<a href="./references#CD013682-bbs2-0072" title="CampbellM , McKenzieJE , SowdenA , KatikireddiSV , BrennanSE , EllisS , et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ2020;368:l6890. [DOI: 10.1136/bmj.l6890]">Campbell 2020</a>; <a href="./references#CD013682-bbs2-0123" title="ReevesBC , DeeksJJ , HigginsJP , SheaB , TugwellP , WellsGA , on behalf of the Cochrane Non-Randomized Studies of Interventions Methods Group. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Reeves 2021</a>).  </p> </section> <section id="CD013682-sec-0042"> <h6 class="title">Non‐randomised studies of interventions</h6> <p>Quantitative and narrative syntheses of NRSI reporting on atopic outcomes were not feasible due to the paucity of studies, the diversity of designs, and the risk of bias judgements (i.e. none were deemed at low or moderate risk of bias). However, these studies are described in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table and <a href="#CD013682-sec-0103">Effects of interventions</a> section. </p> </section> </section> <section id="CD013682-sec-0043"> <h5 class="title">Safety outcomes: serious adverse events and encephalopathy</h5> <p>We pooled RCTs and grouped them by safety endpoints. Data curation and meta‐analyses were performed in <a href="./references#CD013682-bbs2-0121" title="R: A language and environment for statistical computing. Version 4.0.2. Vienna, Austria: R Foundation for Statistical Computing, 2020. Available at www.R-project.org.">R</a>, using the 'dplyr' (<a href="./references#CD013682-bbs2-0148" title="WickhamH , FrançoisR , HenryL , MüllerK . dplyr: a grammar of data manipulation. R package version 1.0.2. Available at: CRAN.R-project.org/package=dplyr2020.">Wickham 2020</a>) and 'meta' packages, respectively (<a href="./references#CD013682-bbs2-0068" title="BalduzziS , RückerG , SchwarzerG . How to perform a meta-analysis with R: a practical tutorial. Evidence-Based Mental Health2019;22(4):153–60. [DOI: 10.1136/ebmental-2019-300117]">Balduzzi 2019</a>). </p> <p>We used the Mantel‐Haenszel method assuming fixed‐effect, to summarise the RR and 95% CIs, without zero‐cell corrections for dichotomous outcomes, instead of stratified meta‐analyses using random‐effects inverse variance methods as initially proposed in our protocol (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>), because the safety outcomes of interest were rare (<a href="./references#CD013682-bbs2-0078" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>; <a href="./references#CD013682-bbs2-0082" title="EfthimiouO . Practical guide to the meta-analysis of rare events. Evidence-Based Mental Health2018;21(2):72–6. [DOI: 10.1136/eb-2018-102911]">Efthimiou 2018</a>). </p> </section> </section> <section id="CD013682-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to undertake the following subgroup analyses:</p> <p> <ul id="CD013682-list-0015"> <li> <p>grouped by age at first dose of pertussis‐containing vaccine: less than three months versus three months or greater; </p> </li> <li> <p>grouped by BCG‐vaccinated versus not BCG‐vaccinated, since the Th<sub>1</sub>‐polarising properties of BCG may prevent atopic dermatitis and other atopic diseases in childhood (<a href="./references#CD013682-bbs2-0133" title="SteenhuisTJ , vanAalderenWM , BloksmaN , NijkampFP , vander LaagJ , vanLoverenH , et al. Bacille-Calmette-Guerinvaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. Clinical and Experimental Allergy2008;38(1):79–85. [DOI: 10.1111/ j.1365-2222.2007.02859.x]">Steenhuis 2008</a>; <a href="./references#CD013682-bbs2-0137" title="ThøstesenLM , KjaergaardJ, PihlGT , BirkNM , NissenTN, AabyP , et al. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: a randomized clinical trial. Allergy2018;73(2):498–504. [DOI: 10.1111/all.13314]">Thøstesen 2018</a>); this in turn could reduce the benefits of priming with wP; </p> </li> <li> <p>grouped by World Bank income level, for studies reporting on atopic outcomes; and,</p> </li> <li> <p>grouped by family history of asthma, atopic dermatitis, food allergy, allergic rhinitis/rhino‐conjunctivitis, or a combination of these in first degree relatives, for studies reporting on atopic outcomes. </p> </li> </ul> </p> <p>Due to a paucity of eligible studies in which the first dose of wP/aP was administered at or after three months old, as well as the small number of RCTs assessing the atopic outcomes of interest, we were unable to carry out subgroup analyses. </p> </section> <section id="CD013682-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out prespecified sensitivity analyses by removing studies judged as high risk of bias and those studies funded by pharmaceutical companies from any meta‐analyses pooling RCTs. Due to a paucity of studies that assessed the atopic outcomes of interest, it was not possible to conduct the prespecified analysis restricted to studies in which 'asthma' or 'current asthma' had been diagnosed after five years of age. </p> </section> <section id="CD013682-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (of GPC, MJE and JR) independently assessed the certainty of the evidence as high, moderate, low or very low, using the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) and standard Cochrane methods (<a href="./references#CD013682-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924–6. [DOI: 10.1136/bmj.39489.470347.AD]">Guyatt 2008</a>; <a href="./references#CD013682-bbs2-0127" title="RyanR , HillS . How to GRADE the quality of evidence. Cochrane Consumers and Communication Group, available at http://cccrg.cochrane.org/author-resources. Version 3.0, December 2016.">Ryan 2016</a>; <a href="./references#CD013682-bbs2-0130" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al, on behalf of the Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) and the Cochrane Statistical Methods Group. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). The comparison of interest was the first dose of wP versus aP before the age of six months, and the following outcomes were assessed: cumulative incidence of atopic disease, diagnosis of IgE‐mediated food allergy, diagnosis of asthma, diagnosis of anaphylaxis (not vaccine‐associated), all‐cause SAEs following immunisation with wP or aP, and diagnosis of encephalopathy. We generated the summary of findings table using GRADEpro GDT software (<a href="./references#CD013682-bbs2-0087" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>), and where synthesis without meta‐analysis was appropriate, we used narrative outcomes. Where justified, we downgraded or upgraded the level of evidence and documented all judgements clearly using written explanations. We prioritised the reporting of the assessments carried out in early infancy (i.e. primary series studies), or at the earliest time point of follow‐up. We resolved discrepancies by discussion or through the arbitration of a third review author (of CBJ, PR, PH or TS). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013682-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013682-sec-0047"></div> <section id="CD013682-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD013682-sec-0049"> <h4 class="title">Results of the search</h4> <p>Our database searches retrieved 13,999 references (CENTRAL, n = 1758; Ovid MEDLINE, n = 6825;  Embase, n = 5416); and we identified further 982 references from the following sources: WHO trial registry (n = 608), clinicaltrials.gov (n = 310), and the website of Sanofi (n = 64). Together they represented 14,981 records that were subsequently managed through <a href="./references#CD013682-bbs2-0083" title="EndNote. The EndNote Team, Version EndNote X9. Philadelphia, PA: Clarivate, 2013.">EndNote X9</a> and <a href="./references#CD013682-bbs2-0076" title="Covidence. Version accessed 9 September 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>, where we removed duplicates. </p> <p>We also screened titles and summaries from Open Grey (n = 16), the GSK trial registry (n = 763), the websites of Pfizer (n = 0), and regulatory assessments completed by the FDA (n = 340) and EMA (n = 36).  We found 11 relevant titles in the references from eligible studies, and one study reported by the EMA that was not retrieved by the relevant trial registry. Together these represented 1166 records, labelled as 'other sources' in the PRISMA flow diagram (<a href="#CD013682-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013682-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD013682-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> <p>After removing duplicates, we assessed a total of 10,650 titles, abstracts and regulatory data, and mapped records related to the same study, with further removal of 10,452 citations. Except for 'other sources', titles and abstracts were screened in <a href="./references#CD013682-bbs2-0076" title="Covidence. Version accessed 9 September 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>. </p> <p>We assessed 95 studies for eligibility (198 records), of which we included 26 (see the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table). Three studies were judged to be ongoing, two were awaiting classification, and 64 were excluded (see the <a href="./references#CD013682-sec-0150" title="">Characteristics of excluded studies</a> table for examples of these). </p> <p>We depicted the flow of information through the different phases of the review using a PRISMA flow chart provided in <a href="#CD013682-fig-0001">Figure 1</a>. </p> </section> <section id="CD013682-sec-0050"> <h4 class="title">Included studies</h4> <section id="CD013682-sec-0051"> <h5 class="title">Studies included in the review for IgE‐mediated food allergy and other atopic outcomes</h5> <section id="CD013682-sec-0052"> <h6 class="title">Study design</h6> <p>This section of the review includes one randomised controlled trial (RCT) (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>), a cohort study (<a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>), a case‐control study (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>), and a post‐hoc analysis of an RCT, where data were treated as an observational longitudinal study to assess whether wP‐, compared to aP‐containing vaccines was associated with a decreased risk of atopic outcomes (<a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>). A further trial ascertained symptoms consistent with early development of atopic diseases (i.e. wheezing, itchy rash, or sneezing) by 2.5 years in 97.8% of the children enrolled, but not the outcomes of interest (<a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>). </p> </section> <section id="CD013682-sec-0053"> <h6 class="title">Recruitment</h6> <p>Children living in the region of Linköping, who were recruited into the Swedish I efficacy, safety and immunogenicity of pertussis vaccines trial (<a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>), were also offered enrolment in the allergy sub‐study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>. Two follow‐up assessments were scheduled at 2.5 and seven years old. We prioritised the earlier point of follow‐up, because the corresponding report explicitly described IgE‐mediated food allergy as one of the outcomes of interest. </p> <p>In non‐randomised studies of interventions (NRSIs), children were recruited antenatally in six hospitals in Sydney, Australia (<a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>) or at birth on the Isle of Wight, UK (<a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>). For the case‐control study (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>), children with a diagnosis of IgE‐mediated food allergy were identified through medical records by specialist allergists from private and tertiary hospital allergy clinics in four out of nine states or territory jurisdictions in Australia. </p> </section> <section id="CD013682-sec-0054"> <h6 class="title">Sample size</h6> <p>This section of the review includes 7333 children across three high‐income countries (Australia, Sweden and the UK), who were followed up between 2.5 and 15 years. </p> </section> <section id="CD013682-sec-0055"> <h6 class="title">Setting</h6> <p>The trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> was carried out in paediatric clinics and primary care centres. In the remaining studies, allergy assessments were undertaken in private and tertiary hospital allergy clinics in four out of nine states or territory jurisdictions in Australia (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>); in two metropolitan hospitals in New South Wales, Australia (<a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>); and in a dedicated specialist allergy research unit on the Isle of Wight, UK (<a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>). </p> </section> <section id="CD013682-sec-0056"> <h6 class="title">Intervention/exposure</h6> <p>Details of the combination vaccines used as intervention or comparator are provided in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. In the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>, children received a first dose of diphtheria‐tetanus‐whole‐cell pertussis vaccine (DTwP) or diphtheria‐ tetanus‐acellular pertussis vaccine (DTaP) between 56 and 92 days old. In the study of <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>, cases and controls were vaccinated with a first dose of DTwP or aP, with or without hepatitis B vaccine before 16 weeks old (DTaP‐HepB or DTaP). The children included in the cohorts of <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a> and <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> received a first dose of wP‐ or aP‐based formulations between six and 18 weeks of age. </p> </section> <section id="CD013682-sec-0057"> <h6 class="title">Co‐interventions and BCG</h6> <p>In the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> the co‐administration of inactivated polio vaccine (IPV), Hib vaccine or both was scheduled with the first dose of DTwP or DTaP. Details of concurrent vaccination were not provided in the reports of NRSIs (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>; <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>). </p> <p>BCG was not included in the relevant national immunisation programmes at the time in which these children were enrolled in these studies, so it is unlikely that they received it before the first dose of pertussis‐containing vaccine. </p> </section> <section id="CD013682-sec-0058"> <h6 class="title">Outcomes</h6> <p>Studies that reported on IgE‐mediated food allergy used confirmation via oral food challenge as the outcome measure (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>: sensitivity analysis) or defined it on the basis of a history of clinical symptoms and proven IgE‐mediated sensitisation via skin‐prick test (SPT) or serum specific IgE (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>; <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>). In the study of Venter 2016, IgE‐mediated food allergy was diagnosed on the basis of either a compatible clinical history or oral food challenge. We followed a prespecified hierarchy of diagnosis and where both were reported separately (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>), we described the results of the association between a first dose of pertussis‐containing vaccine and challenge‐proven IgE‐mediated food allergy. </p> <p>Studies that reported diagnoses of asthma, atopic dermatitis and allergic rhino‐conjunctivitis, provided different and in some cases several time points in their outcome definition (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>; <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>). These are detailed in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> tables. No study assessed anaphylaxis (not vaccine‐associated) as an outcome of interest. Other trials described admissions to hospital for asthma or egg anaphylaxis as serious adverse events (SAEs) (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>). None of these were their prespecified outcomes of interest, nor were their data collected systematically. </p> <p>The overall numbers of children experiencing IgE‐mediated food allergy, allergic rhino‐conjunctivitis, and not‐vaccine associated urticaria by 2.5 years were included in the main report of the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>; however, it was not possible to obtain a breakdown of these data by trial arm. Therefore, we decided to use a broader outcome domain (i.e. cumulative incidence of atopic disease) as prespecified in our protocol, as data were provided as required for this outcome. We estimated these data, and data on the diagnoses of asthma and atopic dermatitis from a bar chart using <a href="./references#CD013682-bbs2-0143" title="WebPlotDigitizer. Version 4.4. Rohatgi A, 2020. Available at automeris.io/WebPlotDigitizer.">WebPlotDigitizer 2020</a>. </p> </section> </section> <section id="CD013682-sec-0059"> <h5 class="title">Studies included in the review for safety</h5> <section id="CD013682-sec-0060"> <h6 class="title">Study design</h6> <section id="CD013682-sec-0061"> <p><b>Primary series studies</b></p> <p>Fourteen primary series studies looked at our prespecified safety outcomes, and were double‐blind, parallel, RCTs (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a> ("trial 2"); <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>). Two used single masking (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>), and five were open‐label (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). Where aP‐based vaccine formulations were allocated to more than one study arm (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>), we combined these data to create a single pairwise comparison. </p> </section> </section> <section id="CD013682-sec-0062"> <h6 class="title">Booster dose studies</h6> <p>Children enrolled in the booster dose study of <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a> received a primary series with wP or aP in a double‐blind, parallel, randomised fashion; however, the primary series study published in 1989 has an unclear length of follow‐up, and therefore, we are not including its data for synthesis. </p> <p>A subset of participants enrolled in the primary series trials of <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>;  <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a> and <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>, completed an additional period of follow‐up after the administration of one or more booster doses of wP‐ or aP‐based formulations. The booster dose studies were reported in separate publications (<a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>;  <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>;) or under a different identifier on clinicaltrials.gov (<a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>). In either case, we linked them to their corresponding primary series study and prioritised the earlier point of safety follow‐up to avoid double counting.  </p> </section> </section> <section id="CD013682-sec-0063"> <h5 class="title">Studies with one or more arms that did not meet prespecified eligibility criteria</h5> <p>Four of the included studies that investigated relevant comparisons and outcomes in this review also included non‐relevant trial arms: <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>, <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a> and <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a> included diphtheria and tetanus toxoids vaccine (DT) as a control arm, and <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a> co‐enrolled a non‐randomised group of infants and allocated them to wP, in accordance with the Thai 'Expanded Programme on Immunization' (EPI) The data from these specific trial arms were not included in this review as they did not meet prespecified inclusion criteria. Further details can be found in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> <section id="CD013682-sec-0064"> <h6 class="title">Recruitment</h6> <p>Infants were recruited in paediatric practices (<a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>), from paediatric outpatient clinics attached to academic institutions (<a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>), via letters to the parents of newborns living in the study catchment area (<a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>), from immunisation clinics (<a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>), in maternal and child health centres (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>), or approached antenatally (<a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>).  </p> </section> <section id="CD013682-sec-0065"> <h6 class="title">Sample size</h6> <p>A total of 137,281 children contributed data in 21 studies that reported our safety outcomes. Sample sizes ranged from 41 to 82,892 children per trial. As detailed in the PRISMA flowchart (<a href="#CD013682-fig-0001">Figure 1</a>), one study did not contribute data to our quantitative syntheses (<a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>, "trial 2"). However, because it met the eligibility criteria for inclusion in this review, we summarise its characteristics below. </p> </section> <section id="CD013682-sec-0066"> <h6 class="title">Location and World Bank income level of country</h6> <p>The studies assessing safety were carried out in Europe (<a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>), North America (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>), Sub‐Saharan Africa (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>), South East Asia (<a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), South America (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>) and the Middle East region (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>). Studies included economies of all‐level income groups, according to the historical classification of the World Bank (<a href="./references#CD013682-bbs2-0149" title="Historical classification by income in XLS format. Available at http://databank.worldbank.org/data/download/site-content/OGHIST.xls (accessed before 21 March 2020).">World Bank 2021</a>). </p> </section> <section id="CD013682-sec-0067"> <h6 class="title">Setting</h6> <p>Community‐based studies in paediatric clinics, general practices, maternal and child health centres or public health units (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>) predominated over trials carried out in clinics attached to academic institutions (<a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), or other healthcare facilities (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). The trial of <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a> was carried out in private paediatric practices and outpatient clinics attached to a local university. </p> </section> <section id="CD013682-sec-0068"> <h6 class="title">Population</h6> <p>Participants were typically healthy infants with an average age of approximately 9.8 weeks on the day of the administration of the first dose of pertussis‐containing vaccine (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). </p> <p>Only one study stratified randomisation by age at enrolment quote: "to minimise bias due to possible age‐associated safety outcomes" (<a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>). The first dose of pertussis‐containing vaccine was given at three months old in the studies carried out by <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>, and in a subset of infants enrolled in the trial of <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>. In the trials of <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a> and <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>, the first dose of pertussis‐containing vaccine was given to healthy infants aged between two and three months old, and two to four months old, respectively. In the remaining studies, infants received their first dose before three months of age. </p> <p>The proportion of children who were male ranged between 49% and 53% across studies (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). Racial and ethnic categories (described in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table as quote: "cultural and ethnic groups") were only reported by three studies (<a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a> used a qualitative statement to describe the infants enrolled in that trial as quote: "ethnically diverse" and "generally similar to the US census population in this region". </p> </section> <section id="CD013682-sec-0069"> <h6 class="title">Intervention</h6> <p>A first dose of wP or aP was administered as a combination vaccine including diphtheria and tetanus toxoids (i.e. DTwP or DTaP; <a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>). Children enrolled in the studies of <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a> were primed with DTwP or DTaP in a previous study published in 1989.  </p> <p>DTwP‐HepB‐Hib (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), DTwP‐Hib‐IPV (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>) and DTwP‐Hib combination vaccines were used in the remaining eligible studies (<a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). Similarly, DTaP‐based vaccine formulations administered in these trials included DTaP‐Hib‐IPV (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>), and DTaP‐HepB‐Hib‐IPV (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). Additional details are provided in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD013682-sec-0070"> <h6 class="title">Co‐interventions and BCG</h6> <p>Fifteen primary series studies reported the type of vaccines co‐administered with the first dose of pertussis‐containing vaccine. The regimens included Hib vaccine (<a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>), oral poliovirus vaccine (OPV) only (<a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>), OPV and Hib vaccine (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>), OPV and hepatitis B vaccine (<a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>), OPV and meningococcal C conjugate vaccine (<a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>), BCG and IPV (<a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>), IPV with or without Hib vaccine (<a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>). Whereas infants primed with a first dose of aP received a concomitant dose of OPV‐placebo (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>), or no concomitant vaccine (<a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), wP vaccinees were immunised with OPV (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), OPV and hepatitis B vaccine (<a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>), or hepatitis B vaccine (<a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>). </p> <p>Five trials did not provide any statement regarding co‐interventions (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>). Children enrolled in the trials of <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a> and <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a> received BCG at birth in accordance with their local EPI. </p> </section> <section id="CD013682-sec-0071"> <h6 class="title">Outcomes and endpoints (outcome domains)</h6> <section id="CD013682-sec-0072"> <p><b>Serious adverse events (SAEs)</b></p> <p>All‐cause SAEs </p> <p>The number of children experiencing at least one SAE could only be extracted from 15 primary series studies (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>), and the booster dose study of <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>. The timing of assessment differed across these studies and is summarised in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> <p>In the primary series trial of <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>, data on events meeting the review definition of SAE were systematically collected from enrolment and reported at five and 18 months after randomisation. Because it is unclear whether any events reported at the 18‐month assessment occurred in children who had previously experienced an SAE, we only included data on the initial five months of follow‐up to avoid double counting.  </p> <p>A similar approach was undertaken to analyse the data from the primary series study, <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>. In the initial stage of this open‐label trial, SAEs were defined as admissions to hospital (all‐cause) occurring within 10 months from enrolment. The investigators of this trial reported the safety data at two time points and it was not possible to determine if the infants with any SAE occurring before the age of five months also had an admission to hospital after this period. To avoid double counting, we only considered the outcomes reported at the earlier time point. </p> <p>In the trial of <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>, we assumed that children were censored after their first SAE, and calculated the total experiencing this outcome from the events reported per 1000 enrolled (i.e. deaths, quote: "other life‐threatening diseases," onset of chronic illness as a proxy of disability, and invasive bacterial infections; the latter were assumed to have led to hospital admission). We attempted to contact the authors of the trial to confirm this assumption, but were unsuccessful. </p> <p><a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a> systematically collected the hospital records of all the infants admitted at any time from enrolment until two months after the third dose of pertussis‐containing vaccine (or eight months old, if series not completed). The FDA summarised the first admission to hospital of the infants enrolled in this trial according to the study arm and dose. Due to probable overlaps between admissions to hospital and other outcome domains, we were unable to extract the total number of infants who experienced any SAE. </p> <p>The trial of <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a> monitored quote: "contacts with the healthcare system for any reason". Although no data regarding these events were included in the peer‐reviewed manuscript, the assessment completed by the FDA does report SAEs following the infant series. </p> <p>Four trials published their safety data on clinicaltrials.gov (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>). We assumed that discrepancies between the number of children experiencing SAEs reported by study arm on the trial registry (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>), and the number affected by specific diagnoses could be explained by the presence of multiple conditions in the same infant at the time of the outcome assessment, or infants that experienced more than one SAE throughout the course of these trials. For clinicaltrials.gov, the definition of SAE not only includes the outcome domains extracted from <a href="./references#CD013682-bbs2-0096" title="International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231–4. [PMID: 11656783]">ICH 1997</a>, but also events that put the child in danger or required medical or surgical intervention to prevent any of the primary safety endpoints of interest for this review. Due to the discrepancies between the definition of SAE used in this review and the one included in the trial registry, these studies were included in the synthesis for 'all‐cause SAE' and where applicable, in the synthesis for 'all‐cause mortality'. Further disagreements between the number of children experiencing SAEs reported by peer‐reviewed articles arising from the studies of  <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a> and <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a> and their corresponding trial registries, are described in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> <p>"Trial 2" published by <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a> warranted additional consideration. Following the introduction of an accelerated two‐, three‐ and 4‐month pertussis immunisation schedule in England in June 1990, the trial of <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a> that compared the safety and immunogenicity of DTwP versus DTaP‐based formulations using a three‐, five‐ and eight‐ to 10‐month schedule, had to be repeated using the new regimen (<a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>). We confirmed with the corresponding author that the records of this study are unavailable, and therefore, we declared the outcome data as missing. </p> <p>In the trial of <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>, children that experienced life‐threatening events (such as post‐vaccination anaphylaxis), were reported as withdrawn due to a definite medical contraindication to pertussis‐containing vaccines, but not counted among those who experienced SAEs. Similarly, deaths during the course of this trial were reported separately. For synthesis purposes, cases of post‐vaccination anaphylaxis and deaths were counted as SAEs. </p> <p><a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a> reported the progress of the children enrolled throughout the study in a CONSORT diagram. Additional information on SAEs was not published on clinicaltrials.gov by 13 March 2021. Because it remains unclear whether SAEs other than deaths occurred during the course of this trial, this study was only included for synthesis on 'all‐cause mortality'. </p> <p>All‐cause mortality </p> <p>Eighteen primary series trials  (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>) and one booster dose study (<a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>) provided information allowing us to extract data on deaths. Because the study of <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a> only planned to report data on sudden infant death syndrome (SIDS), we did not include it in the related meta‐analysis.  </p> <p>Events leading to admission to hospital (all‐cause) </p> <p>Nine primary series trials (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>) and one booster dose study (<a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>) reported information on hospital admissions. The timing of assessment differed across these studies and is summarised in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table.  </p> <p>In a personal communication, the corresponding author of the trial of <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a> confirmed that serious adverse reactions following immunisation did not lead to admission to hospital, and therefore, these events do not meet the regulatory definition of SAE considered in this review. It is unclear whether any SAEs unrelated to the study vaccines resulted in hospitalisation. </p> <p>The trial of <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a> only collected data on admissions to hospital for events contraindicating further vaccination with pertussis‐containing vaccines or for events that met their protocol definition of serious. The FDA assessment summarises the number of admissions to hospital per study arm occurring within 30 days of vaccination; nevertheless, we could not conclude from the report whether children were censored for this outcome domain after their first hospitalisation.  </p> <p><a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a> collected data on events requiring admission to hospital, but details are only provided for children hospitalised for serious infections. </p> <p>Events described as life‐threatening </p> <p>Here we included trials that provided information on this specific outcome domain (<a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>), those which did not include life‐threatening events in their methods section but systematically collected data on post‐vaccination anaphylaxis (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>), and those that reported the occurrence of anaphylaxis after any dose without further details (<a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>). </p> <p>The trial of <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a> assessed post‐vaccination anaphylaxis and events described as life‐threatening as separate study outcomes; however, the investigators only reported on vaccine‐associated anaphylaxis. The corresponding author estimated the number of children with other life‐threatening events in a personal communication. </p> <p>The EMA reported adverse life‐threatening events for a single arm of the comparison of interest (i.e. infants vaccinated with an aP‐based vaccine formulation in the trials of <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a> and <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). Peer‐reviewed publications arising from these trials do not describe whether these data were systematically collected. </p> <p>Events leading to persistent or significant disability or incapacity </p> <p>Four studies contributed data to this outcome domain. One collected data on quote: "any illness resulting in sequelae" (<a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>), and three reported on the onset of chronic illnesses, a proxy of disability (<a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>). <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a> collected data on events defined as "permanently disabling", but results were not included in the publication assessed in this review. An author of the trial provided an estimate of the number of children who met this study endpoint through personal correspondence. </p> </section> <section id="CD013682-sec-0073"> <p><b>Diagnosis of encephalopathy</b></p> <p>Seven primary‐series RCTs (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>) and one booster dose study (<a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>) contributed safety data regarding encephalopathy for both relevant arms of the comparison. The timing of assessment differed across these trials and is summarised in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> <p>The EMA reported encephalopathy for a single arm of the comparison of interest (i.e. infants vaccinated with an aP‐based vaccine formulation in the trials of <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a> and <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). Peer‐reviewed publications arising from these trials do not describe whether these data were systematically collected. </p> </section> </section> </section> <section id="CD013682-sec-0074"> <h5 class="title">Ongoing studies and studies awaiting classification</h5> <p>We identified three studies that are ongoing that may be eligible for inclusion in this review when complete (<a href="./references#CD013682-bbs2-0062" title="ACTRN12617000065392. Optimising immunisation using mixed schedules (OPTIMUM): comparing allergic outcomes in infants following pertussis vaccination [A double-blind, randomised, controlled trial to compare allergic outcomes in children following vaccination with acellular pertussis antigen given at 2 months of age versus whole cell pertussis in the infant vaccine schedule]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000065392 (date submitted 15 December 2016). ">ACTRN12617000065392</a>; <a href="./references#CD013682-bbs2-0063" title="ISRCTN17271364. A study exploring whooping cough protection in infants following vaccination [A randomised, open label study, exploring the differences in immunogenicity and reactogenicity of infants after immunisation with either an acellular (aP) or whole cell pertussis (wP) vaccine]. isrctn.com/ISRCTN17271364 (date applied 27 January 2020). [DOI: doi.org/10.1186/ISRCTN17271364]University of Oxford. A randomised, open label study, exploring the differences in immunogenicity and reactogenicity of infants after immunisation with either an acellular (aP) or whole cell pertussis (wP) vaccine ‐ Pertussis acellular whole cell advanced research (AWARE) study. Available at: www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-001789-13-GB, 20192019. [EUCTR-001789-13-GB,]">ISRCTN17271364</a>; <a href="./references#CD013682-bbs2-0064" title="NCT03606096. Gambia pertussis study (GaPs) [Randomised, double-blinded, open label study in pregnant women, exploring the impact of acellular pertussis vaccination in pregnancy on the immunogenicity in infants randomized to receive either an acellular (aP) or whole cell pertussis (wP) vaccine subsequently]. clinicaltrials.gov/ct2/show/study/NCT03606096 (first posted 30 July 2018). Perez ChaconG . Re: GaPs study query! [personal communication]. Email to: B Kampmann 20 March 2019. ">NCT03606096</a>). Further details are included in <a href="./references#CD013682-sec-0152" title="">Characteristics of ongoing studies</a>. </p> <p>We also identified two studies where we were unable to make a judgment on eligibility. We were unable to source the report for <a href="./references#CD013682-bbs2-0060" title="European Medicines Agency. Infanrix Hexa - EPAR- scientific discussion; 2005. Available at www.ema.europa.eu/en/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf. GlaxoSmithKline. A phase III, open randomised clinical study to assess the immunogenicity and reactogenicity of SBBiologicals’ Haemophilus influenzae type b conjugate vaccine co-administered with SB Biologicals’ combined diphtheria tetanus-acellular pertussis-hepatitis B-inactivated polio vaccine(DTPa-HBV-IPV) in one single injection or as two separate injections, in comparison with Pasteur-Mérieux-Connaugh't’s combined diphtheria-tetanus-whole-cell pertussis-inactivated polio Haemophilus influenzae type b vaccine (Pentacoq™) coadministered with SB Biologicals’ hepatitis B vaccine as two concomitant injections in opposite limbs, given to healthy infants as a primary vaccination course at 2, 3 and 4 months of age. No longer available. ">217744/025 (DTPa‐HBV‐IPV‐025)</a>, as this was no longer available through the GSK trial registry. For <a href="./references#CD013682-bbs2-0061" title="JedrychowskiW , WhyattRM , CamannDE , BawleUV , PekiK , SpenglerJD , et al. Effect of prenatal PAH exposure on birth outcomes and neurocognitive development in a cohort of newborns in Poland. Study design and preliminary ambient data. International Journal of Occupational Medicine and Environmental Health2003;16(1):21–9. [PMID: 12705714]Mrozek-BudzynD , MajewskaR , KieltykaA , AugustyniakM . Whole-cell pertussis vaccine (DTwP) has no influence on allergic diseases and atopic sensitization in children. Postepy Dermatologii i Alergologii2018;35(4):381–6. [DOI: 10.5114/ada.2018.77668]">Mrozek‐Budzyn 2018</a>, the age of the first dose of wP/aP was not stated in the report. In either case, our attempts to contact the sponsor of <a href="./references#CD013682-bbs2-0060" title="European Medicines Agency. Infanrix Hexa - EPAR- scientific discussion; 2005. Available at www.ema.europa.eu/en/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf. GlaxoSmithKline. A phase III, open randomised clinical study to assess the immunogenicity and reactogenicity of SBBiologicals’ Haemophilus influenzae type b conjugate vaccine co-administered with SB Biologicals’ combined diphtheria tetanus-acellular pertussis-hepatitis B-inactivated polio vaccine(DTPa-HBV-IPV) in one single injection or as two separate injections, in comparison with Pasteur-Mérieux-Connaugh't’s combined diphtheria-tetanus-whole-cell pertussis-inactivated polio Haemophilus influenzae type b vaccine (Pentacoq™) coadministered with SB Biologicals’ hepatitis B vaccine as two concomitant injections in opposite limbs, given to healthy infants as a primary vaccination course at 2, 3 and 4 months of age. No longer available. ">217744/025 (DTPa‐HBV‐IPV‐025)</a>, or the lead and senior authors of the study of <a href="./references#CD013682-bbs2-0061" title="JedrychowskiW , WhyattRM , CamannDE , BawleUV , PekiK , SpenglerJD , et al. Effect of prenatal PAH exposure on birth outcomes and neurocognitive development in a cohort of newborns in Poland. Study design and preliminary ambient data. International Journal of Occupational Medicine and Environmental Health2003;16(1):21–9. [PMID: 12705714]Mrozek-BudzynD , MajewskaR , KieltykaA , AugustyniakM . Whole-cell pertussis vaccine (DTwP) has no influence on allergic diseases and atopic sensitization in children. Postepy Dermatologii i Alergologii2018;35(4):381–6. [DOI: 10.5114/ada.2018.77668]">Mrozek‐Budzyn 2018</a> were unsuccessful. Further details are available in <a href="./references#CD013682-sec-0151" title="">Characteristics of studies awaiting classification</a>. </p> </section> </section> <section id="CD013682-sec-0075"> <h4 class="title">Excluded studies</h4> <p>Sixty‐four studies were excluded from this review at the full‐text screening stage. Thirty‐three examples of these are listed with reasons for exclusion in the <a href="./references#CD013682-sec-0150" title="">Characteristics of excluded studies</a> table. </p> <p>The reasons for exclusion of studies reporting on atopy or atopic outcomes were: no comparison of interest (<a href="./references#CD013682-bbs2-0029" title="BernsenRM , KoesBW , deJongsteJC , van derWoudenJC . Haemophilus influenzae type b vaccination and reported atopic disorders in 8-12-year-old children. Pediatric Pulmonology2006;41(5):463–9. [DOI: 10.1002/ppul.20397]">Bernsen 2006</a>; <a href="./references#CD013682-bbs2-0031" title="FarooqiIS , HopkinJM . Early childhood infection and atopic disorder. Thorax1998;53(11):927–32. [DOI: 10.1136/thx.53.11.927]">Farooqi 1998</a>; <a href="./references#CD013682-bbs2-0032" title="GrüberC , IlliS , LauS , NickelR , ForsterJ , KaminW , et al. Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics2003;111(3):e282–8. [DOI: 10.1542/peds.111.3.e282]NickelR , LauS , NiggemannB , GruberC , Von MutiusE , IlliS , et al. Messages from the German Multicentre Allergy Study. Pediatric Allergy and Immunology2002;13(15):7–10. ">Grüber 2003</a>; <a href="./references#CD013682-bbs2-0033" title="GrüberC , WarnerJ , HillD , BauchauV . Early atopic disease and early childhood immunization--is there a link?Allergy2008;63(11):1464–72. [DOI: 10.1111/j.1398-9995.2008.01696.x]">Grüber 2008</a>; <a href="./references#CD013682-bbs2-0039" title="HendersonJ , NorthK , GriffithsM , HarveyI , GoldingJ . Pertussis vaccination and wheezing illnesses in young children: prospective cohort study. The Longitudinal Study of Pregnancy and Childhood Team. BMJ1999;318(7192):1173–6. ">Henderson 1999</a>; <a href="./references#CD013682-bbs2-0040" title="KummelingI , ThijsC , StelmaF , HuberM , vanden BrandtPA , DagneliePC . Diphtheria, pertussis, poliomyelitis, tetanus, and Haemophilus influenzae type b vaccinations and risk of eczema and recurrent wheeze in the first year of life: the KOALA birth cohort study. Pediatrics2007;119(2):e367–73. [DOI: 10.1542/peds.2006-1479]">Kummeling 2007</a>; <a href="./references#CD013682-bbs2-0041" title="MaitraA , SherriffA , GriffithsM , HendersonJ , Avon Longitudinal Study of Parents, Children Study Team. Pertussis vaccination in infancy and asthma or allergy in later childhood: birth cohort study. BMJ2004;328(7445):925–6. [DOI: 10.1136/bmj.38045.858889]PhipatanakulW . Pertussis vaccination in infancy and asthma or allergy in later childhood: birth cohort study. Pediatrics2005;116(2):541–2. [DOI: 10.1542/peds.2005-0698M]">Maitra 2004</a>;  <a href="./references#CD013682-bbs2-0042" title="MathesonMC , Haydn WaltersE , BurgessJA , JenkinsMA , GilesGG , et al. Childhood immunization and atopic disease into middle-age--a prospective cohort study. Pediatric Allergy and Immunology2010;21(2):301–6. [DOI: 10.1111/j.1399-3038.2009.00950.x]">Matheson 2010</a>;  <a href="./references#CD013682-bbs2-0043" title="McDonaldKL , HuqSI , LixLM , BeckerAB , KozyrskyjAL . Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma. Journal of Allergy and Clinical Immunology2008;121(3):626–31. [DOI: 10.1016/j.jaci.2007.11.034]">McDonald 2008</a>; <a href="./references#CD013682-bbs2-0044" title="McKeever TM , Lewis SA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985–9. [DOI: 10.2105/ajph.94.6.985]">McKeever 2004</a>; <a href="./references#CD013682-bbs2-0045" title="MulloolyJP , SchulerR , BarrettM , MaherJE . Vaccines, antibiotics, and atopy. Pharmacoepidemiology and Drug Safety2007;16(3):275–88. [DOI: doi.org/10.1002/pds.1272]">Mullooly 2007</a>; <a href="./references#CD013682-bbs2-0053" title="SwartzJ , AronssonB , LindbladF , Järnbert-PetterssonH , ScheyniusA , PershagenG , et al. Vaccination and allergic sensitization in early childhood - The ALADDIN birth cohort. EClinicalMedicine2018;4-5:92–8. [DOI: 10.1016/j.eclinm.2018.10.005]">Swartz 2018</a>; <a href="./references#CD013682-bbs2-0054" title="ThomsonJA , WidjajaC , DarmaputraAA , LoweA , MathesonMC , BennettCM , et al. Early childhood infections and immunisation and the development of allergic disease in particular asthma in a high-risk cohort: a prospective study of allergy-prone children from birth to six years. Pediatric Allergy and Immunology2010;21(7):1076–85. ">Thomson 2010</a>), and no comparison (<a href="./references#CD013682-bbs2-0057" title="Perez ChaconG . Re: query: Hib combination vaccine and atopic disorders: a prospective cohort study [personal communication]. Email to P Chen 12 December 2020. WangIJ , HuangLM , GuoYL , HsiehWS , LinTJ , ChenPC . Haemophilus influenzae type b combination vaccines and atopic disorders: a prospective cohort study. Journal of the Formosan Medical Association2012;111(12):711–8. [DOI: 10.1016/j.jfma.2011.09.022]">Wang 2012</a>; <a href="./references#CD013682-bbs2-0059" title="Yamamoto-HanadaK , PakK , Saito-AbeM , YangL , SatoM , MezawaH , et al. Cumulative inactivated vaccine exposure and allergy development among children: a birth cohort from Japan. Environmental Health and Preventive Medicine2020;25(1):27. [DOI: 10.1186/s12199-020-00864-7]">Yamamoto‐Hanada 2020</a>). </p> <p>The study of <a href="./references#CD013682-bbs2-0056" title="VogtH , BrabackL , KlingAM , GrunewaldM , NilssonL . Pertussis immunization in infancy and adolescent asthma medication. Pediatrics2014;134(4):721–8. [PMID: 10.1542/peds.2014-0723]">Vogt 2014</a> warranted additional consideration. This observational study compared a cohort of children enrolled in the trial of <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>, with children unvaccinated with pertussis antigens who were born five months before the start date of the RCT, or seven months after its end date, using "dispensed prescribed asthma medication" as a proxy of asthma. Therefore, it was classified as ineligible. </p> <p>The reasons for exclusion for safety studies were length of follow‐up shorter than six months (<a href="./references#CD013682-bbs2-0027" title="AndersonEL , BelsheRB , BartramJ . Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. Journal of Infectious Diseases1988;157(4):731–7. [DOI: https://doi.org/10.1093/infdis/157.4.731]">Anderson 1988</a>; <a href="./references#CD013682-bbs2-0028" title="AndersonEL , MinkCM , BerlinBS , ShihCN , TungFF , BelsheRB . Acellular pertussis vaccines in infants: evaluation of single component and two-component products. Vaccine1994;12(1):28–31. [PMID: 10.1016/0264-410x(94)90007-8]">Anderson 1994</a>; <a href="./references#CD013682-bbs2-0034" title="Ball, L. Clinical Review of BLA STN 103907: InfanrixDTPaHepB-IPVTM . Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM106897.pdf2001. GylcaR , GylcaV , BenesO , MelnicA , ChicuV , WeisbeckerC , et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine2000;19(7):825–33. ">Gylca 2000</a>; <a href="./references#CD013682-bbs2-0035" title="HalperinSA , BarretoL , EastwoodBJ , LawB , RobertsEA . Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Archives of Pediatrics &amp; Adolescent Medicine1994;148(11):1220–4. [DOI: 10.1001/archpedi.1994.02170110106025]">Halperin 1994</a>; <a href="./references#CD013682-bbs2-0036" title="HalperinSA , MillsE , BarretoL , PimC , EastwoodBJ . Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatric Infectious Disease Journal1995;14(9):792-7. [DOI: 10.1097/00006454-199509000-00012]">Halperin 1995</a>; <a href="./references#CD013682-bbs2-0037" title="HalperinSA , ScheifeleD , BarretoL , PimC , GuaspariniR , MeddL , et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatric Infectious Disease Journal1999;18(9):772-9. [DOI: 10.1097/00006454-199909000-00006]">Halperin 1999</a>; <a href="./references#CD013682-bbs2-0038" title="HalperinSA , ScheifeleD , MillsE , GuaspariniR , HumphreysG , BarretoL , et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine2003;21(19):2298–306. [DOI: 10.1016/s0264-410x(03)00173-7]">Halperin 2003</a>; <a href="./references#CD013682-bbs2-0046" title="PichicheroME , FrancisAB , BlatterMM , ReisingerKS , GreenJL , MarsocciSM , et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics1992;89(5):882–7. [PMID: 1579399]PichicheroME , FrancisAB , MarsocciSM , GreenJL , DisneyFA , MeschievitzC . Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics1993;91(4):756–60. [PMID: 8464662]">Pichichero 1992</a>; <a href="./references#CD013682-bbs2-0047" title="PichicheroME , FrancisAB , MarsocciSM , GreenJL , DisneyFA . Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants. American Journal of Diseases of Children1993;147(3):295–9. [DOI: 10.1001/archpedi.1993.02160270057018]">Pichichero 1993</a>; <a href="./references#CD013682-bbs2-0048" title="PichicheroME , GreenJL , FrancisAB , MarsocciSM , LyndAM , LitteerT . Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children. Pediatric Infectious Disease Journal1994;13(3):193–6. [DOI: 10.1097/00006454-199403000-00005]">Pichichero 1994</a>; <a href="./references#CD013682-bbs2-0049" title="PichicheroME , GreenJL , FrancisAB , MarsocciSM , MurphyAM , BuscarinoC . Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scandinavian Journal of Infectious Diseases1996;28(2):159–63. [DOI: 10.3109/00365549609049068]">Pichichero 1996</a>;  <a href="./references#CD013682-bbs2-0050" title="PoddaA , BonaG , CancianiG , PistilliAM , ContuB , FurlanR , et al. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Journal of Pediatrics1995;127(2):238–43. [DOI: 10.1016/s0022-3476(95)70301-2]PoddaA , De La LucaEC , ContuB , FurlanR , MaidaA , MoiraghiA , et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. Journal of Pediatrics1994;124(6):921–6. [DOI: 10.1016/s0022-3476(05)83181-6]">Podda 1994</a>; <a href="./references#CD013682-bbs2-0052" title="SimondonF , YamA , GagnepainJY , WassilakS , DanveB , CadozM . Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. European Journal of Clinical Microbiology &amp; Infectious Diseases1996;15(12):927–32. ">Simondon 1996</a>; <a href="./references#CD013682-bbs2-0055" title="VanuraH , JustM , AmbroschF , BergerRM , BogaertsH , WynenJ , et al. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine. Vaccine1994;12(3):210–4. [DOI: 10.1016/0264-410x(94)90196-1]">Vanura 1994</a>; <a href="./references#CD013682-bbs2-0058" title="WiersbitzkyS , BockHL , BrunsR , ClemensR , GraulG , KoditzH , et al. Reactogenicity and immunogenicity of a three-component acellular pertussis DTPa vaccine compared to the conventional whole-cell DTPg vaccine. Monatsschr Kinderheilkd1996;144(2):159–66. ">Wiersbitzky 1996</a>); age at the first dose of pertussis‐containing vaccine (<a href="./references#CD013682-bbs2-0030" title="BlennowM , GranströmM , JäätmaaE , OlinP . Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics1988;82(3):293–9. BlennowM , GranströmM , OlinP , TiruM , JäätmaaE , AskelöfP , et al. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6. Developments in Biological Standardization1986;65:185–90. BlennowM , GranstromM . Sixteen-month follow-up of antibodies to pertussis toxin after primary immunization with acellular or whole cell vaccine. Pediatric Infectious Disease Journal1989;8(9):621–5. TindbergY , BlennowM , GranstromM . A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatric Infectious Disease Journal1999;18(4):361–5. [DOI: 10.1097/00006454-199904000-00011]">Blennow 1988</a>); and study design (household contact study; <a href="./references#CD013682-bbs2-0051" title="SchmittHJ , vonKonigCH , NeissA , BogaertsH , BockHL , Schulte-WissermannH , et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA1996;275(1):37–41. [PMID: 8531284]">Schmitt 1996</a>). </p> </section> </section> <section id="CD013682-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD013682-sec-0077"> <h4 class="title">Studies included in the review for atopic outcomes</h4> <section id="CD013682-sec-0078"> <h5 class="title">Randomised controlled trials</h5> <p>In <a href="#CD013682-fig-0002">Figure 2</a> we provide our judgement for each risk of bias category for the study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> (figure generated using robvis; <a href="./references#CD013682-bbs2-0105" title="McGuinness, LA, Higgins, JP. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods2021;12(1):55–61. [DOI: doi.org/10.1002/jrsm.1411]">McGuinness 2020</a>). </p> <div class="figure" id="CD013682-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: judgement of the review authors about each risk of bias item for each included randomised controlled trial" data-id="CD013682-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: judgement of the review authors about each risk of bias item for each included randomised controlled trial </p> </div> </div> </div> <section id="CD013682-sec-0079"> <h6 class="title">Allocation (blinding)</h6> <p>The study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> enrolled a subset of children randomised in the trial of <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>. Therefore, the two trials each share the same judgements on the risk of bias arising from random sequence generation (low) and allocation concealment (unclear). </p> </section> <section id="CD013682-sec-0080"> <h6 class="title">Blinding (performance bias and detection bias)</h6> <p>Because partial unblinding of the wP arm, but not the aP/DT arms occurred in the trial of <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>, we judged the study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> at unclear risk of bias for this domain. Additional information is provided in the <a href="./references#CD013682-sec-0149" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD013682-sec-0081"> <h6 class="title">Incomplete outcome data (attrition bias)</h6> <p>In the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>, children who were not fully immunised, or who had incomplete follow‐up data were not included in the analyses. Other reasons for non‐completion include withdrawal of consent, and moving house away from the study area. The dropout rates cannot be calculated by study arm because the numbers randomised into each intervention group are not reported. This study was judged to be at unclear risk of bias due to incomplete outcome data. </p> </section> <section id="CD013682-sec-0082"> <h6 class="title">Selective reporting (reporting bias)</h6> <p> The study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> was judged to be at unclear risk of bias since the data on IgE‐mediated food allergy was not made available by study group.  </p> </section> </section> <section id="CD013682-sec-0083"> <h5 class="title">Non‐randomised studies of interventions</h5> <p>See <a href="#CD013682-tbl-0002">Table 1</a>; <a href="#CD013682-tbl-0003">Table 2</a>; <a href="#CD013682-tbl-0004">Table 3</a>; <a href="#CD013682-tbl-0005">Table 4</a>; <a href="#CD013682-tbl-0006">Table 5</a>; <a href="#CD013682-tbl-0007">Table 6</a>; <a href="#CD013682-tbl-0008">Table 7</a> and <a href="#CD013682-fig-0003">Figure 3</a> (figure generated using robvis; <a href="./references#CD013682-bbs2-0105" title="McGuinness, LA, Higgins, JP. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods2021;12(1):55–61. [DOI: doi.org/10.1002/jrsm.1411]">McGuinness 2020</a>) for our risk of bias assessments for <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>; <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>; and <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>. </p> <div class="table" id="CD013682-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of challenge‐proven IgE‐mediated food allergy before 15 years old</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriately adjusted for surrogates of vaccine availability (date of birth and jurisdiction at vaccination) </p> <p>Potentially insufficient adjustment for socioeconomic status. Family history of atopy and breastfeeding could not have  influenced the allocation to the intervention as this was largely dependent on vaccine availability. The method used to minimise confounding was direct matching </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This is a retrospective case‐control study. The selection of cases was based on the outcome of interest. The exposure distribution in the controls is likely to represent the exposure status of the overall cohort, as controls were selected from the Australian Immunisation Register irrespective of their past or future case status  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was well‐defined and based on information collected at the time of the intervention  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information reported  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The association between vaccination status and challenge‐proven IgE‐mediated food allergy was tested through a sensitivity analysis, carried out according to the study protocol. Therefore, outcome data were only available for a non‐random subset of cases with a history of food allergic reaction coupled with IgE‐mediated sensitisation to the food of interest and a positive oral food challenge. </p> <p>A small number of children were excluded due to missing data on the exposure status. These data were likely to be missing at random </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome assessors reviewed the medical records while blinded to the vaccination status. They determined whether a child met the primary outcome (clinical criteria of food allergy and evidence of sensitisation to the food that may have caused the allergic reaction), and whether there was a clinical record of a positive oral food challenge to that food at any time. </p> <p>During the follow‐up period, vaccination status would not have influenced the decision to challenge a child with the food of interest<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study data were analysed according to a prespecified sensitivity analysis.</p> <p>There is no evidence of selective reporting.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This risk of bias assessment was based on the data included in a sensitivity analysis (i.e. a non‐random subset of cases). </p> <p>There are some concerns regarding missing outcome data, insufficient adjustment for socioeconomic status and lack of adjustment by birth order </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013682-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at five yearsa </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information</p> <p>available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome data were available for nearly all children.<sup>b</sup>A small proportion of children was excluded due to incomplete information on the exposure of interest </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to have been influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Risk of bias judgements are also applicable for the outcomes: diagnosis of asthma (current asthma) at 18 months and 3 years </p> <p><sup>b</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0016"> <li> <p>Current asthma at 18 months: wP = 0/293; 0.00%. aP = 1/204; 0.49%</p> </li> <li> <p>Current asthma at 3 years: wP = 9/293; 3.07%. aP= 8/204; 3.92%</p> </li> <li> <p>Current asthma at 5 years:  wP = 15/293; 5.12%. aP = 14/204; 6.86%</p> </li> </ul> </p> </div> </div> <div class="table" id="CD013682-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at eight years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by  knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0017"> <li> <p>Current asthma by 8 years: wP = 59/293; 20.14%. aP = 30/204; 14.71%</p> </li> </ul> </p> </div> </div> <div class="table" id="CD013682-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 11.5 years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status is well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is higher in aP vaccinees than in recipients of wP. <sup>a</sup> </p> <p>However, this is unlikely to be related to the exposure status. The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by  knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0018"> <li> <p>Current asthma by 11.5 years: wP = 83/293; 28.3%. aP = 76/204; 37.25%</p> </li> </ul> </p> </div> </div> <div class="table" id="CD013682-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 14 years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is high but balanced across the study groups.<sup>a</sup> The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0019"> <li> <p>Current asthma by 14 years: wP = 105/293; 35,84%. aP= 72/204; 35.29%</p> </li> </ul> </p> </div> </div> <div class="table" id="CD013682-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of IgE‐mediated food allergy (on the basis of either a compatible clinical history or oral food challenge) by 10 yearsa </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaccine allocation is described as 'almost at random, depending on the supply of the particular vaccine, avoiding potential biases due to secular trends in the risk of developing atopic disease'. </p> <p>The authors defined family history of asthma/hay fever, breastfeeding and sex as potential confounders; however, they were unlikely to have influenced the assignment of the study vaccines. Adjustment was made via multivariable binomial regression. No adjustment by date of birth, birth order and socioeconomic status was performed, 'as the number of cases was not sufficiently robust' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome data were available for nearly all children.<sup>b</sup> A small proportion of children was excluded due to incomplete information on the exposure of interest </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not find the protocol of this study. However, there is no evidence of selective reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Also applicable for the outcome: diagnosis of asthma by 3 years </p> <p><sup>b</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0020"> <li> <p>Diagnosis of challenge proven IgE‐mediated food allergy: wP = 4/595; 0.67%. aP = 1/224; 0.45% </p> </li> <li> <p>Diagnosis of asthma by 3 years: wP = 35/595; 5.88%. aP = 20/224; 8.93%</p> </li> </ul> </p> </div> </div> <div class="table" id="CD013682-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of asthma by 10 years of age</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaccine allocation is described as 'almost at random, depending on the supply of the particular vaccine, avoiding potential biases due to secular trends in the risk of developing atopic disease'. </p> <p>The authors defined family history of asthma/hay fever, breastfeeding and sex as potential confounders; however, they were unlikely to have influenced the assignment of the study vaccines. Adjustment was made via multivariable binomial regression. No adjustment by date of birth, birth order and socioeconomic status was performed, 'as the number of cases was not sufficiently robust' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in this cohort study. </p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is high, but balanced across the study groups.<sup>a</sup> The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not find the study protocol or statistical analysis plan of this study. However, there is no evidence of selective reporting<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding, and concerns abound missing data<br/> <br/>  </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0021"> <li> <p>Diagnosis of asthma by 10 years: wP = 259/595; 43.53%. aP = 112/224; 50.00%</p> </li> </ul> </p> </div> </div> <div class="figure" id="CD013682-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias: 'traffic light' plot of the domain‐level judgements for each individual result of non‐randomised studies of interventions according to the ROBINS‐tool" data-id="CD013682-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias: 'traffic light' plot of the domain‐level judgements for each individual result of non‐randomised studies of interventions according to the ROBINS‐tool </p> </div> </div> </div> <p>The following risk of bias assessments examined the effect of assignment of the intervention/exposure at baseline. The consensus decisions for the signalling questions are available as <a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 1</a>. </p> <section id="CD013682-sec-0084"> <h6 class="title">Bias due to confounding</h6> <p>Ecological analyses of publicly available data have shown an increase in the number of admissions to hospital ICD‐coded as anaphylaxis following the transition from wP to aP vaccine schedules in Australia, between 1997 and 1999. There is little reason to expect that the receipt of wP or aP was influenced by factors other than calendar time, and chance during the switchover from wP to aP formulations in Australia, and also on the Isle of Wight (UK) when a period of shortage of wP meant that some children received aP instead. Family history of allergic diseases, gestational age at delivery and breastfeeding status are unlikely to have influenced the allocation of the intervention/exposure which was largely driven by the availability of the vaccine in the surgeries of general practitioners or immunisation clinics on the day of vaccination. Therefore, we only included in our assessments confounding domains relevant for these settings (i.e. availability of the vaccine, using date of birth as a proxy; socioeconomic status and birth order). One study was judged as moderate risk of bias for confounding (Estcourt 2020; diagnosis of challenge‐proven IgE‐mediated food allergy) and two at serious risk (Toelle 2020; diagnosis of asthma and Venter 2016; diagnoses of challenge‐proven IgE‐mediated food allergy and asthma). </p> </section> <section id="CD013682-sec-0085"> <h6 class="title">Bias in selection of participants into the study</h6> <p>We judged two studies to be at low risk of bias (Toelle 2020; Venter 2016); this is because the selection of children into the analyses was not dependent on characteristics observed after the first dose of pertussis‐containing vaccine. In the study of Estcourt 2020, cases were identified from among children diagnosed by specialist allergists with a case‐based sampling approach used to mitigate any selection bias. Using the ROBINS‐I tool (version 1, August 2016; Sterne 2016a), the risk of bias for this domain was deemed to be moderate. </p> </section> <section id="CD013682-sec-0086"> <h6 class="title">Bias in the classification of pertussis‐containing vaccines</h6> <p>We judged all of the studies reporting on primary and secondary atopic outcomes as low risk of bias. The exposure groups were clearly defined and their classification is unlikely to have been influenced by knowledge of the outcome status. </p> </section> <section id="CD013682-sec-0087"> <h6 class="title">Bias due to deviations from intended pertussis‐containing vaccine</h6> <p>This domain of the ROBINS‐I tool refers to the biases that occur as a result of quote: "systematic differences between the care provided to experimental intervention and comparator groups, beyond the assigned interventions" (<a href="./references#CD013682-bbs2-0135" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info [accessed before April 2021].">Sterne 2016b</a>). There is no information available to judge whether there was bias due to deviations from intended intervention for any of the relevant studies. </p> </section> <section id="CD013682-sec-0088"> <h6 class="title">Bias due to missing data</h6> <p>The definition of complete dataset for diagnosis of IgE‐mediated food allergy varies according to the outcome measure chosen. In this case, decisions were supported by a prespecified hierarchy of diagnosis described in the protocol of this review. In the study of Venter 2016 the diagnosis was on the basis of either a compatible clinical history or oral food challenge. In this case,  outcome data were available for nearly all children. </p> <p>In the study of <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>, challenge‐proven IgE‐mediated food allergy was described in a pre‐planned sensitivity analysis of a non‐random subset of cases with a history of food hypersensitivity coupled with IgE‐mediated sensitisation to the food of interest. In both studies, a small number of children were excluded due to missing data on the exposure status. Although these data were likely to be missing at random, ROBINS‐I states that this is a marker of potential bias. Therefore, for the primary outcome of this review, the study of Venter 2016 was judged as moderate risk bias due to missing data. Restricting the analysis to those cases confirmed through oral food challenge, the study of Estcourt 2020 was judged to be at serious risk of bias. </p> <p>For the secondary outcome diagnosis of asthma, data were available for nearly all children at the follow‐up assessments completed at 18 months, three and five years old, and we rated them as moderate risk of bias due to missing data. In contrast, decreasing completeness was noted in the assessments scheduled at 10, 11.5 and 14 years old, with analyses unlikely to have addressed the impact of missing data on the validity of the results. Therefore, we rated these studies to be at serious or critical risk for this domain. </p> </section> <section id="CD013682-sec-0089"> <h6 class="title">Bias in measurement of outcomes</h6> <p>We judged all studies to be at low risk of bias (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>; <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>), as the methods of outcome measurement were considered comparable across the study groups, outcome measures were unlikely to be influenced by knowledge of the intervention received, and errors in their measurement were unlikely to be related to intervention status. </p> </section> <section id="CD013682-sec-0090"> <h6 class="title">Bias in selection of the reported result</h6> <p>The study of <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a> was pre‐registered on clinicaltrials.gov and its prespecified analysis plan is also available as a peer‐reviewed publication; thus, it was judged to be at low risk of bias for this domain. We did not find the study protocol or statistical analysis plan of the study of <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>, and the analyses presented in the study of <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> were declared post hoc. In each case, outcome measures were clearly defined and there is no evidence of selective reporting; therefore, we judged them at moderate risk of bias for selection of the reported result. </p> </section> <section id="CD013682-sec-0091"> <h6 class="title">Overall risk of bias assessment</h6> <p>We rated all of the NRSIs to be at serious or critical risk of bias, and therefore, not eligible for quantitative or narrative synthesis. The domains contributing to this judgment were 'confounding' and 'missing data'. </p> </section> <section id="CD013682-sec-0092"> <h6 class="title">Other potential sources of bias</h6> <section id="CD013682-sec-0093"> <p><b>Funding</b></p> <p>The study of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> received funding from public and private agencies. NRSIs received funding from the National Health and Medical Research Council of Australia (NHMRC) and Public Health England, as well as other government funding agencies and academic institutions. Details are provided in the Characteristics of included studies table. </p> </section> <section id="CD013682-sec-0094"> <p><b>Declarations of interest</b></p> <p>Investigators for three of the NRSIs declared conflicts of interest. Details are provided in the Characteristics of included studies table. </p> </section> </section> </section> </section> <section id="CD013682-sec-0095"> <h4 class="title">Randomised controlled trials included in the review for safety</h4> <p>See <a href="#CD013682-fig-0002">Figure 2</a> for the risk of bias summary for the RCTs that assessed safety outcomes, where we provide our judgement for each risk of bias category (figure generated using robvis; <a href="./references#CD013682-bbs2-0105" title="McGuinness, LA, Higgins, JP. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods2021;12(1):55–61. [DOI: doi.org/10.1002/jrsm.1411]">McGuinness 2020</a>). We judged seven studies to be at high risk of bias (<a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>), and the remaining at unclear risk. </p> </section> <section id="CD013682-sec-0096"> <h4 class="title">Allocation</h4> <p>We judged  five studies to be at low risk of bias for sequence generation (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>) and the remaining at unclear risk. For allocation concealment, the studies of <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a> and <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a> were deemed at low risk of bias, and the remaining trials at unclear risk. </p> </section> <section id="CD013682-sec-0097"> <h4 class="title">Blinding</h4> <p>Where encephalopathy was assessed as an outcome of interest, the studies were judged to be at unclear (<a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>), or high risk of performance bias (<a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>). We considered that the primary safety outcome and associated endpoints were unlikely to be influenced by knowledge of the intervention received, and therefore, we judged all the studies reporting on them (but not on encephalopathy) at low risk of performance bias. </p> <p>We assessed five studies as being at low risk for detection bias due to a detailed explanation of the strategies implemented to keep the outcome assessors blinded to the vaccine allocation (<a href="https://revman.cochrane.org/421643922681657828" target="_blank">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="https://revman.cochrane.org/421643922681657815" target="_blank">Olin 1997</a>), or because the assessment of the outcome domain of interest (i.e. deaths from any cause) was unlikely to be influenced by knowledge of the intervention received (<a href="https://revman.cochrane.org/421643922681657744" target="_blank">Afari 1996</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). In contrast, we judged open‐label trials at high risk for detection bias (<a href="https://revman.cochrane.org/421643922681657722" target="_blank">Dagan 1997</a>; <a href="https://revman.cochrane.org/421643922681657658" target="_blank">Kitchin 2006</a>; <a href="https://revman.cochrane.org/421643922681657825" target="_blank">Madhi 2011</a>; <a href="https://revman.cochrane.org/421643922681657788" target="_blank">Reinert 2006</a>). </p> </section> <section id="CD013682-sec-0098"> <h4 class="title">Incomplete outcome data</h4> <p>One trial was judged as high risk of bias due to low retention rates (<a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>), and four at low risk of bias owing to low rates of dropout (<a href="https://revman.cochrane.org/421643922681657684" target="_blank">Gustafsson 1996</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="https://revman.cochrane.org/422554206610148164" target="_blank">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>); the remaining were assessed as unclear risk. </p> </section> <section id="CD013682-sec-0099"> <h4 class="title">Selective reporting</h4> <p>Two trials were judged as high risk of bias for selective reporting (<a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>). The trial of <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a> reported on reactogenicity of pertussis‐containing vaccines, but not on SAEs following immunisation. Similarly, the trial of <a href="https://revman.cochrane.org/421643922681657768" target="_blank">Stehr 1998</a> only described admissions to hospital due to serious infections, in spite of the methods specifying that events requiring hospitalisation were going to be systematically reported irrespective to their relatedness to the study vaccines. </p> <p>Among the trials pre‐registered on clinicaltrials.gov., three were judged as low risk of bias (<a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>), and two as unclear risk due to apparent inconsistencies between the trial registry and peer‐reviewed publications (<a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>). Although we could not source the extended technical reports and pre‐planned statistical analysis plan of the trial of <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>, this study was judged as low risk of bias, because the data on the outcomes prespecified in the methods of this study were systematically collected and reported. The remaining trials were judged to be at unclear risk (see <a href="https://revman.cochrane.org/CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table). </p> </section> <section id="CD013682-sec-0100"> <h4 class="title">Other potential sources of bias</h4> <section id="CD013682-sec-0101"> <h5 class="title">Funding</h5> <p>Eight trials received funding from vaccine manufacturers (<a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0017" title="NCT00343889. Comparison of DTaP-HB-PRP~T combined vaccine to Tritanrix-HepB/Hib™, both given concomitantly with oral polio vaccine [Immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix-HepB/Hib™, both given concomitantly with the oral polio vaccine at 6, 10, and 14 weeks of age in healthy infants in the Philippines]. clinicaltrials.gov/ct2/show/record/NCT00343889?view=record (first posted 10 December 2013). NCT00534833. Immunogenicity study of antibody persistence and booster effect of DTaP-HB-PRP~T combined vaccine or Tritanrix-HepB/Hib™ [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine or Tritanrix HepB/Hib™ at 15 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00534833 (first posted 26 September 2007). ">NCT00343889</a>; <a href="./references#CD013682-bbs2-0018" title="NCT00348881. Study comparing a DTaP-HB-PRP~T combined vaccine with Tritanrix HepB/Hib™, concomitantly with OPV in healthy infants [Large scale safety and immunogenicity study of a DTaP-Hep B-PRP-T combined vaccine compared to Tritanrix HepB/Hib™, both given concomitantly with OPV at 6, 10, and 14 weeks of age in healthy Filipino infants]. clinicaltrials.gov/ct2/show/record/NCT00348881 (first posted 22 October 2013). NCT00514709. Immunogenicity study of antibody persistence and booster effect of DTaP-HB PRP~T combined vaccine in Filipino infants [Immunogenicity study of the antibody persistence and booster effect of DTaP-Hep B-PRP-T combined vaccine at 12 to 18 months of age following a primary series at 6, 10 and 14 weeks of age in healthy Filipino infants having received hepatitis B vaccine at birth]. clinicaltrials.gov/ct2/show/record/NCT00514709 (first posted 2 August 2016). ">NCT00348881</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>); four were carried out through research grants from the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Health (NIH) in the USA (<a href="./references#CD013682-bbs2-0005" title="ChristyC , PichicheroME , ReedGF , DeckerMD , AndersonEL , RennelsMB , et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):584–7. [PMID: 7659481]DeckerMD , EdwardsKM , SteinhoffMC , RennelsMB , PichicheroME , EnglundJA , et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics1995;96(3):557–66. [PMID: 7659476]DeckerMD , EdwardsKM . The multicenter acellular pertussis trial: an overview. Journal of Infectious Diseases1996;174(Suppl 3):S270–5. [DOI: 10.1093/infdis/174.supplement_3.s270]DeloriaMA , BlackwelderWC , DeckerMD , EnglundJA , SteinhoffMC , PichicheroME , et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics1995;96(3):592–4. [PMID: 7659483]EdwardsKM , MeadeBD , DeckerMD , ReedGF , RennelsMB , SteinhoffMC , et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics1995;96(3 Pt 2):548–57. [PMID: 7659475]EnglundJA , AndersonEL , ReedGF , DeckerMD , EdwardsKM , PichicheroME , et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics1995;96(3):580–4. [PMID: 7659480]KleinDL . A phase II multicenter evaluation of several candidate pertussis vaccines in infants. Developments in Biological Standardization1991;73:305–9. [PMID: 1778324]MeadeBD , DeforestA , EdwardsKM , RomaniTA , LynnF , O'BrienCH , et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics1995;96(3):570–5. [PMID: 7659478]Perez ChaconG . Multicenter acellular pertussis trial - data request [personal communication]. Email to: JA Englund 19 April 2020. PichicheroME , AndersonEL , RennelsMB , EdwardsKM , EnglundJA . Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatric Infectious Disease Journal2001;20(4):427–33. [DOI: 10.1097/00006454-200104000-00011]PichicheroME , ChristyC , DeckerMD , SteinhoffMC , EdwardsKM , RennelsMB , et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics1995;96(3):588–92. [DOI: 7659482]PichicheroME , DeloriaMA , RennelsMB , AndersonEL , EdwardsKM , DeckerMD , et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics1997;100(5):772–8. [DOI: 10.1542/peds.100.5.772]PichicheroME , EdwardsKM , AndersonEL , RennelsMB , EnglundJA , YergDE , et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics2000;105(1):e11. [DOI: doi: 10.1542/peds.105.1.e11]RennelsMB , ReedGF , DeckerMD , EdwardsKM , PichicheroME , DeloriaMA , et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines. Pediatrics1995;96(3):576–9. [PMID: 7659479]SteinhoffMC , ReedGF , DeckerMD , EdwardsKM , EnglundJA , PichicheroME , et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics1995;96(3):567–70. [PMID: 7659477]US Food &amp; Drug Administration. Clinical review - Infanrix; May 2003 [Clinical review of supplement to license application for Infanrix®(diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed) to include fifth dose indication]. Available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm103006.htm Accessed on 25 January 2021. US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Decker 1995</a>; <a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-bbs2-0009" title="AusielloCM , UrbaniF , la SalaA , LandeR , CassoneA . Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and Immunity1997;65(6):2168–74. [DOI: 10.1128/IAI.65.6.2168-2174.1997]AusielloCM , UrbaniF , La SalaA , LandeR , PiscitelliA , CassoneA . Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Developments in Biological Standardization1997;89:315–20. [PMID: 9272365]Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]CossoneA , AusielloCM , UrbaniF , LandeR , GiulianoM , SalaAL , et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Archives of Pediatrics &amp; Adolescent Medicine1997;151(3):283–9. [DOI: 10.1001/archpedi.1997.02170400069013]GiulianoM , MastrantonioP , GiammancoA , BottoneM , PiscitelliA , Di TommasoS , et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Developments in Biological Standardization1997;89:315–20. [PMID: 9272360]GiulianoM , MastrantonioP , GiammancoA , PiscitelliA , SalmasoS , WassilakSG . Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics1998;132(6):938–8. [DOI: 10.1016/s0022-3476(98)70395-6]GrecoD , SalmasoS , MastrantonioP , GiulianoM , The Italian Pertussis Working Group. Clinical trial of acellular pertussis vaccines in Italy - Study design. Biologicals1993;21(1):38. [DOI: 10.1006/biol.1993.1036]GrecoD , SalmasoS , MastrantonioP , GiulianoM , TozziAE , AnemonaA , et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine1996;334(6):341–8. [DOI: 10.1056/NEJM199602083340601]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]SalmasoS , AnemonaA , MastrantonioP , StefanelliP , TozziAE , Ciofi degli AttiML . Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Developments in Biological Standardization1998;95:189–94. [PMID: 9855431]SalmasoS , MoiraghiA , BaraleA , FerraroP , Dal LagoP , CoppolaN , et al. Case definitions. Developments in Biological Standardization1997;89:135–42. SalmasoS , PiscitelliA , RapicettaM , ChionneP , MadonnaE , ArgentiniC . Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine1998;16(6):643–6. [DOI: 10.1016/s0264-410x(97)00231-4]TozziAE , Ciofi degli AttiML , WassilakSG , SalmasoS , PaneiP , AnemonaA , et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine1998;16(2):320–2. [DOI: 10.1016/s0264-410x(97)00163-1]Tozzi AE , GrecoD , SalmasoS , WassilakSG . Pertussis immunization: results of new trials. Pediatric Pulmonology Supplement1997;16:282–3. [DOI: 10.1002/ppul.19502308146]Tozzi AE , OlinP . Common side effects in the Italian and Stockholm I trials. Developments in Biological Standardization1997;89:105–8. [PMID: 9272339]US Federal Drug &amp; Administration. Summary basis of approval. Diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM244609.pdf. ">Greco 1996</a>; <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a>); two were funded by the UK Medical Research Council (<a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>; <a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>); one by multiple academic and research institutions (<a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>) and three were supported by public and private funding schemes (i.e. the trial of  <a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a> was sponsored by the Government of Ghana and the Research Foundation for Microbial Diseases of Osaka University, a bio‐pharmaceutical group; the study of <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a> by the NIAID NIH and three manufacturers which also provided the DTaP formulations; and the study of <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a> was sponsored by a pharmaceutical company and the <i>Office de la Recherche Scientifique et Technique Outre‐mer</i> , a French public research institution today known as <i>Institut de Recherche Pour le Développement</i>). In four trials, funding was not disclosed (<a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>). </p> </section> <section id="CD013682-sec-0102"> <h5 class="title">Declarations of interest</h5> <p>Only four trials declared conflicts of interest (<a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0013" title="European Medicines Agency. EMA/373968/2013 Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. European Medicines Agency EMA/373868/2013. Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. MacíasM , LanataCF , ZambranoB , GilAI , AmemiyaI , MispiretaM , et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatric Infectious Disease Journal2012;31(8):e126–32. [DOI: 10.1097/INF.0b013e318258400d]NCT00313911. Safety of DTaP-IPV-Hep B-PRP~T combined vaccine compared to Tritanrix-HepB/Hib™ and OPV given at age 2, 4, and 6 months [Large scale safety study of a DTaP-IPV-Hep B-PRP~T combined vaccine, in comparison to Tritanrix-Hep B/Hib™ and OPV administered at 2, 4, and 6 months of age in Latin American infants]. clinicaltrials.gov/ct2/show/NCT00313911 (first posted 19 November 2012). ">Macías 2012</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0026" title="NCT02408926. Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand [Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand]. clinicaltrials.gov/ct2/show/NCT02408926 (first posted 6 April 2015). PosuwanN , WanlapakornN , VongpunsawadS , SintusekP , LeuridanE , Van DammeP , et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine2020;38(7):1643–51. [DOI: 10.1016/j.vaccine.2019.12.065]WanlapakornN , MaertensK , ThongmeeT , SrimuanD , ThatsanathornT , Van DammeP , et al. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine2020;38(44):6914–21. [DOI: 10.1016/j.vaccine.2020.08.058]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases2020;71(1):72–80. [DOI: 10.1093/cid/ciz778]WanlapakornN , MaertensK , VongpunsawadS , PuenpaJ , TranTM , HensN , et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clinical Infectious Diseases2020;71(1):72–80. Figure, The Consolidated Standards for Reporting Trials flow diagram; p. 71. [DOI: 10.1093/cid/ciz778]">Wanlapakorn 2020</a>). Among the remaining studies where no disclosure was made, one or more investigators were employees of a vaccine manufacturer (<a href="./references#CD013682-bbs2-0001" title="AfariEA , KamiyaY , NkrumahFK , DunyoSK , AkpedonuP , KamiyaH , et al. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Annals of Tropical Paediatrics1996;16(1):39–48. [DOI: 10.1080/02724936.1996.11747802]">Afari 1996</a>; <a href="./references#CD013682-bbs2-0002" title="BlackSB , ShinefieldHR , BergenR , HartC , KremersR , LavetterA , et al. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Disease Journal1997;16(1):53–8. [DOI: 10.1097/00006454-199701000-00012]Perez ChaconG . Query re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to: SB Black 21 January 2021. ">Black 1997</a>; <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0004" title="DaganR , IgbariaK , PiglanskyL , MelamedR , WillemsP , GrossiA , et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatric Infectious Disease Journal1997;16(12):1113–21. [DOI: 10.1097/00006454-199712000-00004]Perez ChaconG . Queries re: whole-cell versus acellular pertussis vaccine study published in PIDJ, 1997 [personal communication]. Email to R Dagan 21 January 2021. ">Dagan 1997</a>; <a href="./references#CD013682-bbs2-0008" title="FeldmanS , PerryCS , AndrewM , JonesL , MoffittJE , LambD , et al. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids. Southern Medical Journal1993;86(3):269–75, 284. [PMID: 8451663]">Feldman 1993</a>; <a href="./references#CD013682-bbs2-0011" title="HalperinSA , EastwoodBJ , BarretoL , FriesenB , MeddL , MeekisonW , et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine1996;14(8):767–72. [DOI: 10.1016/0264-410x(95)00250-5]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Halperin 1996</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>; <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>; <a href="./references#CD013682-bbs2-0023" title="CherryJD , HeiningerU , StehrK , ChristensonP . The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics1998;102(4):909–12. [DOI: 10.1542/peds.102.4.909]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeiningerU , CherryJD , StehrK , Schmitt-GrohéS , UberallM , LaussucqS , et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics1998;102(3):546–53. [DOI: 10.1542/peds.102.3.546]HeiningerU , StehrK , ChristensonP , CherryJD . Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clinical Infectious Diseases1999;28(3):602–4. [DOI: 10.1086/515154]LugauerS , HeiningerU , CherryJD , StehrK . Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. European Journal of Pediatrics2002;161(3):142–6. [DOI: 10.1007/s00431-001-0893-5]Perez ChaconG . RE: efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine [personal communication]. Email to: JD Cherry 10 March 2021. SchlapferG , CherryJD , HeiningerU , UberallM , Schmitt-GroheS , LaussucqS , et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatric Infectious Disease Journal1995;14(3):209–14. [DOI: 10.1097/00006454-199503000-00008]Schmitt-GrohéS , StehrK , CherryJD , HeiningerU , UberallMA , LaussucqS , et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:113–8. [PMID: 9272341]StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , UberallM , LaussucqS , et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics1998;101(1):1–11. [DOI: 10.1542/peds.101.1.1]StehrK , CherryJD . A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Developments in Biological Standardization1997;89:58–62. [PMID: 9333571]TapiainenT , Cherry JD , HeiningerU . Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine2005;23(43):5106–12. [DOI: 10.1016/j.vaccine.2005.05.039]UberallMA , StehrK , CherryJD , HeiningerU , Schmitt-GrohéS , LaussucqS , et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Developments in Biological Standardization1997;89:83–9. [PMID: 9272335]">Stehr 1998</a>), one received DTwP manufactured by Wellcome as a donation (<a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>) and one a pertussis vaccine antigen (69 kDa or pertactin) from Connaught Laboratories (<a href="./references#CD013682-bbs2-0016" title='MillerE , AshworthLA , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: 10.1016/s0264-410x(96)00112-0]Perez Chacon G. Queries re: "trial II" Effect of schedule on reactogenicity and whole-cell pertussis vaccine. Email to E Miller 05 May 2021. '>Miller 1997</a>). </p> </section> </section> </section> <section id="CD013682-sec-0103"> <h3 class="title" id="CD013682-sec-0103">Effects of interventions</h3> <p>See: <a href="./full#CD013682-tbl-0001"><b>Summary of findings 1</b> Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</a> </p> <p>We report atopic and safety outcomes for the comparison: first dose as wP versus first dose aP before the age of six months. </p> <section id="CD013682-sec-0104"> <h4 class="title">Atopic outcomes</h4> <section id="CD013682-sec-0105"> <h5 class="title">Cumulative incidence of atopic disease</h5> <p>One RCT was suitable for narrative synthesis (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>). This study was carried out in Sweden in the early 1990s, in a setting with lower prevalence of IgE‐mediated food allergy than identified in more recent cohorts. Because data on (our prespecified primary outcome (IgE‐mediated food allergy) could not be sourced by study arm (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>), we chose to report on the cumulative incidence of atopic disease outcome and calculated a risk ratio (RR) and 95% confidence interval (CI), as prespecified in our protocol (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>). This broader outcome domain encompasses children who were diagnosed with at least one of the following atopic diseases: IgE‐mediated food allergy, asthma, atopic dermatitis, urticaria and allergic rhino‐conjunctivitis by 2.5 years old. </p> <p>This small study was statistically underpowered to detect a reduction in their chosen endpoints (except for a large reduction &gt; 50%). Using GRADE, we assessed the evidence as of very low certainty.  We downgraded by one level for indirectness, and two for imprecision, since the existence of effect in either direction remains plausible (RR 0.85, 95%CI 0.62 to 1.17; 497 children; <a href="./references#CD013682-fig-0007" title="">Analysis 1.1</a>). </p> </section> <section id="CD013682-sec-0106"> <h5 class="title">Diagnosis of IgE‐mediated food allergy</h5> <p>NRSIs that reported diagnosis of challenge‐proven IgE‐mediated food allergy (<a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>) were not eligible for narrative synthesis due to serious risk of bias (<a href="#CD013682-fig-0003">Figure 3</a>). This decision was made according to the protocol of this review (<a href="./references#CD013682-bbs2-0151" title="Perez ChaconG , EstcourtM , RamsayJ , Brennan-JonesC , HoltP , SnellingT . Whole-cell pertussis vaccine in infancy for the prevention of allergy. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013682. [DOI: 10.1002/14651858.CD013682]">Perez Chacon 2020</a>). The details of the risk of bias assessments are provided in <a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 1</a>. </p> </section> <section id="CD013682-sec-0107"> <h5 class="title">Diagnosis of anaphylaxis</h5> <p>None of the included studies investigated our prespecified outcome of diagnosis of anaphylaxis (not vaccine‐associated). </p> </section> </section> <section id="CD013682-sec-0108"> <h4 class="title">Diagnosis of asthma</h4> <p>In <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>, asthma was diagnosed in 15 of 137 children vaccinated with wP (10.95%), and 38 of 360 children vaccinated with aP (10.56%) by 2.5 years of age. There was insufficient evidence to determine whether wP may change the risk of asthma diagnosis by 2.5 years (RR 1.04; 95% CI 0.59 to 1.82; 497 children; very low certainty; <a href="./references#CD013682-fig-0008" title="">Analysis 1.2</a>). Although the investigators of this study argue that most of the study participants diagnosed with asthma had a previous history of atopic dermatitis, with or without evidence of IgE‐mediated sensitisation, it is plausible that some of them may have been 'transient (episodic) wheezers'. These children have been reported to mainly wheeze in the context of upper respiratory viral infections, with no or minimal symptoms between episodes, and lack of eosinophilic inflammation (<a href="./references#CD013682-bbs2-0117" title="PavordID , BeasleyR , AgustiA , AndersonGP , BelE , BrusselleG , et al . After asthma: redefining airways diseases. Lancet2018;391(10118):350-400. [DOI: 10.1016/S0140-6736(17)30879-6]">Pavord 2018</a>). This wheezing phenotype explains a large proportion of wheezing episodes in preschool‐aged children, and we believe that is unlikely to be affected by wP priming. Therefore, we downgraded by one level for indirectness, and by two levels for imprecision, as the CI of the effect size is wide, and includes the null effect. </p> <p>NRSI that reported diagnosis of asthma (<a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>; <a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a>) were not eligible for narrative synthesis due to serious or critical risk of bias (<a href="#CD013682-fig-0003">Figure 3</a>). </p> </section> <section id="CD013682-sec-0109"> <h4 class="title">Diagnosis of atopic dermatitis</h4> <p>In the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>, atopic dermatitis was diagnosed by 2.5 years old in 23 of 137 (16.79%) children vaccinated with wP and 81 out of 360 vaccinated with aP (22.5%). There was insufficient evidence to determine whether wP may affect the risk of atopic dermatitis (RR 0.75; 95% CI 0.49 to 1.13, 497 children; low‐certainty evidence; <a href="./references#CD013682-fig-0009" title="">Analysis 1.3</a>). Therefore we downgraded the evidence by two levels for imprecision. </p> </section> <section id="CD013682-sec-0110"> <h4 class="title">Other atopic outcomes</h4> <p>Data on diagnoses of urticaria and allergic rhino‐conjunctivitis could not be sourced by study arm (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>). </p> </section> <section id="CD013682-sec-0111"> <h4 class="title">Safety outcomes</h4> <section id="CD013682-sec-0112"> <h5 class="title">Primary series studies</h5> <section id="CD013682-sec-0113"> <h6 class="title">All‐cause serious adverse events</h6> <p>One or more SAEs occurred in 153 of 14,183 children allocated at random to a first dose of wP (1.09%), and in 277 out of 23,889 recipients allocated to a first dose of aP (1.16%). The Mantel‐Haenszel RR without continuity correction was 0.94 (95% CI 0.78 to 1.15; I<sup>2</sup> = 0%; 15 primary series studies, 38,072 children; <a href="#CD013682-fig-0004">Figure 4</a>). For every 1000 infants primed with a first dose of aP before six months old, 12 experienced an SAE; the corresponding risk for wP was 11 (95% CI 9 to 13). Compared to aP, the 95% CI around the absolute risk difference of SAE for children receiving a first dose of wP ranged from three fewer to two more SAEs per 1000 vaccinees. </p> <div class="figure" id="CD013682-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause serious adverse events" data-id="CD013682-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause serious adverse events </p> </div> </div> </div> <p>Removing studies at high risk of bias left 11 studies in the analysis (RR 0.94, 95% CI 0.77 to 1.16; I<sup>2</sup> = 8%; 29,576 children), without changes to the interpretation of the result. The exclusion of studies funded by pharmaceutical companies resulted in moderate heterogeneity (RR 0.98, 95% CI 0.63 to 1.51; I<sup>2</sup> = 44%; six studies, 20,105 children), but no change in the conclusion. </p> <p>Using GRADE, we assessed the evidence as moderate certainty (downgraded one level for imprecision). </p> </section> <section id="CD013682-sec-0114"> <h6 class="title">All‐cause mortality</h6> <p>We included 18 studies, involving 134,541 children, in the analysis. Deaths were reported in 54 out of 40,908 children vaccinated with a first dose of wP before 6 months (0.13%), and in 74 of 93,633 aP‐vaccinees (0.08%). Therefore, the proportion of children who died during the follow‐up period was greater in wP compared to aP‐vaccinees, but the confidence interval was wide around the RR of 1.01 (95% CI  0.71 to  1.45; I<sup>2</sup> = 0%; <a href="#CD013682-fig-0005">Figure 5</a>), indicating substantial imprecision. </p> <div class="figure" id="CD013682-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause mortality" data-id="CD013682-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause mortality </p> </div> </div> </div> <p>We tested the robustness of these findings through prespecified sensitivity analyses, removing studies at high risk of bias (RR 1.04, 95% CI 0.71 to 1.52; I<sup>2</sup> = 0%; 13 studies, 117,513 children), and by excluding trials that were funded by pharmaceutical companies. For the latter, we removed the studies that had the greatest contribution to the weighted average, including <a href="./references#CD013682-bbs2-0022" title="HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]LacombeK , YamA , SimondonK , PinchinatS , SimondonF . Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine2004;23(5):623–8. [DOI: 10.1016/j.vaccine.2004.07.007]PreziosiMP , NdiayeM , Coll-SeckA , SimondonF . The Senegal pertussis trial: safety and surveillance of adverse reactions. Developments in Biological Standardization1997;89:91–7. [PMID: 9272336]SimondonF , PreziosiMP , YamA , KaneCT , ChabirandL , ItemanI , et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine1997;15(15):1606–12. [DOI: 10.1016/s0264-410x(97)00100-x]SimondonF . Senegal pertussis trial. Developments in Biological Standardization1997;89:63–6. [PMID: 9333572]VoseJR , HoffenbachA . Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens. Biologicals1999;27(2):97–8. [DOI: 10.1006/biol.1999.0188]">Simondon 1997</a>, which was carried out in a rural area of Senegal, with an infant mortality rate of 85 per 1000 live births. In this case, we observed a decrease in both the Mantel‐Haenszel RR and the precision of the estimate (RR 0.62, 95% CI 0.12 to 3.30; I<sup>2</sup> = 0%; seven studies, 25,150 children); however, there was no resulting change in the interpretation of the results. </p> <p>Using GRADE, we assessed the evidence as low certainty (downgraded two levels for imprecision). </p> </section> <section id="CD013682-sec-0115"> <h6 class="title">Events leading to admission to hospital</h6> <p>We included eight studies in this analysis. At least one admission to hospital was reported in 122 out of 6011 children vaccinated with a first dose of wP before six months (2.03%), and in 306 out of 12,319 aP‐vaccinees (2.48%). The Mantel‐Haenszel RR without continuity correction for all‐cause admission to hospital was 0.98 (95% CI 0.80 to 1.21; I<sup>2</sup> = 2%; 18,330 children; <a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 2</a>). </p> <p>We carried out prespecified sensitivity analyses to assess the robustness of the main result, by removing studies at high risk of bias (RR 0.98, 95% CI 0.80 to 1.20; I<sup>2</sup> = 30%; six studies, 17,592 children) and by excluding studies funded by vaccine manufacturers (RR 0.99, 95% CI 0.80 to 1.22; I<sup>2</sup> = 32%; six studies, 13,314 children) without meaningful changes in the point estimates, CIs or interpretation of the findings. </p> <p>Using GRADE, we assessed the evidence as low certainty (downgraded two levels for imprecision). </p> </section> <section id="CD013682-sec-0116"> <h6 class="title">Events described as life‐threatening</h6> <p>Eight studies were pooled for this meta‐analysis; four contributed no events. One or more events described as life‐threatening were reported in four out of 37,376 children vaccinated with a first dose of wP before the age of six months (0.01%), and in nine out of 87,353 aP‐vaccinees (0.01%). The Mantel‐Haenszel RR with no continuity correction was 1.08  (95% CI 0.32 to 3.64; I<sup>2</sup> = 0%; 124,729 children, <a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 2</a>). The reported number of children with this outcome was few and the confidence interval around the RR was wide. </p> <p>Exclusion of studies at high risk of bias (RR 0.88, 95% CI 0.25 to 3.17; I<sup>2</sup> = 0%; five studies, 108,860 children) did not cause any major changes in the CI. A decrease in the Mantel‐Haenszel RR and greater statistical heterogeneity were detected after removing studies funded by vaccine manufacturers (RR 0.55, 95% CI 0.07 to 4.62; I<sup>2</sup> = 23%; four studies, 21,934 children), however this did not result in meaningful changes in the interpretation of the main findings. </p> <p>Using GRADE, we assessed the evidence as of low certainty (downgraded two levels for imprecision). </p> </section> <section id="CD013682-sec-0117"> <h6 class="title">Events leading to persistent or significant disability or incapacity</h6> <p>Four studies were pooled for this meta‐analysis; two contributed no events. At least one event leading to disability was reported in six out of 7008 children vaccinated with a first dose of wP before six months of age (0.09%), and in 9 out of 14,966 aP‐vaccinees (0.06%). The CI was wide around the RR of 1.45 (95% CI 0.51 to 4.16; I<sup>2</sup> = 39%; 21,974 children, <a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 2</a>). No changes were observed after excluding one study judged to be at high risk of bias and funded by a pharmaceutical company (RR of 1.45, 95% CI 0.51 to 4.16; I<sup>2</sup> = 39%; 21,733 children). </p> <p>Using GRADE, we assessed the evidence as of low certainty (rated down two levels for imprecision). </p> </section> <section id="CD013682-sec-0118"> <h6 class="title">Diagnosis of encephalopathy</h6> <p>Seven primary series studies systematically collected data on encephalopathy, but no events were reported in 32,268 recipients of wP and 83,003 aP‐vaccinees (<a href="./references#CD013682-fig-0010" title="">Analysis 1.4</a>). A 95% CI was calculated using the score method (<a href="./references#CD013682-bbs2-0112" title="NewcombeRG . Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in medicine1998;17(8):873-90. [PMID: 9595617]">Newcombe 1998</a>). This is a serious outcome, and although the 95% CI around the absolute difference is narrow (‐5 per 100,000 to 12 per 100,000), we could not rule out a clinically meaningful difference. Using GRADE we assessed the evidence as low certainty (downgraded two levels for imprecision). </p> </section> <section id="CD013682-sec-0119"> <h6 class="title">Booster dose study</h6> <p>Within two years of follow‐up after a booster dose of DTaP, no SAEs (deaths or events leading to hospitalisation), or diagnoses of encephalopathy were reported in children who were randomly allocated to a primary series of DTwP (n = 23) or DTaP (n = 18) (<a href="./references#CD013682-bbs2-0006" title="EdwardsKM , BradleyRB , DeckerMD , PalmerPS , Van SavageJ , TaylorJC , et al. Evaluation of a new highly purified pertussis vaccine in infants and children. Journal of Infectious Diseases1989;160(5):832–7. [DOI: 10.1093/infdis/160.5.832]EdwardsKM , DeckerMD , BradleyRB , TaylorJC , HagerCC . Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal1991;10(4):315–8. [DOI: 10.1097/00006454-199104000-00010]">Edwards 1991</a>; <a href="./references#CD013682-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD013682-fig-0012" title="">Analysis 1.6</a>). In either case, using GRADE, we assessed the evidence as being of low certainty (downgraded two levels for imprecision). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013682-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013682-sec-0120"></div> <section id="CD013682-sec-0121"> <h3 class="title" id="CD013682-sec-0121">Summary of main results</h3> <p>This review includes four studies that reported on our primary and secondary atopic outcomes of interest, and 21 trials reporting on serious adverse events (SAEs) and/or encephalopathy for our comparison of interest (first dose of whole‐cell pertussis (wP) vaccine versus acellular pertussis (aP) vaccine in infants younger than six months). </p> <p>Evidence on atopic outcomes was of very low certainty and we were unable to draw any conclusions on the relative effects of wP versus aP vaccines on atopic diseases (<a href="./full#CD013682-tbl-0001">summary of findings Table 1</a>. Meta‐analyses of the allergy outcome data were not feasible due to the paucity of randomised controlled trials (RCTs) and high‐quality non‐randomised studies of interventions (NRSIs) assessing IgE‐mediated food allergy and/or asthma as study outcomes, and heterogeneity in the designs of existing studies. In addition, serious or critical risk of bias across the outcomes reported by three NRSIs precluded their inclusion in a narrative synthesis. As prespecified in the study protocol, we grouped the atopic outcomes reported by the trial of <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> using a broader outcome domain (i.e. cumulative incidence of atopic diseases at 2.5 years). We also synthesised narratively, the evidence regarding diagnoses of asthma and atopic dermatitis, arising from the same study. No study planned to assess non vaccine‐associated anaphylaxis as an outcome of interest, yet one ongoing study considers clinician‐diagnosed food anaphylaxis as evidence of IgE‐mediated food allergy (<a href="./references#CD013682-bbs2-0062" title="ACTRN12617000065392. Optimising immunisation using mixed schedules (OPTIMUM): comparing allergic outcomes in infants following pertussis vaccination [A double-blind, randomised, controlled trial to compare allergic outcomes in children following vaccination with acellular pertussis antigen given at 2 months of age versus whole cell pertussis in the infant vaccine schedule]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000065392 (date submitted 15 December 2016). ">ACTRN12617000065392</a>). This RCT is expected to provide more definitive evidence on protection against early onset of IgE‐mediated food allergy in a setting with high prevalence. </p> <p>The incidence of all‐cause SAEs was within the expected range for otherwise healthy infants, and similar for wP and aP. The 95% confidence interval (CI around the absolute difference ranged from a potential decreased to an increased risk (<a href="./full#CD013682-tbl-0001">summary of findings Table 1</a>), unlikely to be clinically meaningful.  </p> <p>The evidence regarding risk of encephalopathy was obtained only through studies that identified no events  (<a href="./full#CD013682-tbl-0001">summary of findings Table 1</a>). The absolute difference between wP and aP was 0%, with a 95% CI ranging from ‐0.005% to 0.012%. Although the CI is narrow, encephalopathy is a serious condition and therefore, we could not rule out a clinically meaningful difference. </p> </section> <section id="CD013682-sec-0122"> <h3 class="title" id="CD013682-sec-0122">Overall completeness and applicability of evidence</h3> <section id="CD013682-sec-0123"> <h4 class="title">Completeness of evidence</h4> <p>We undertook a comprehensive review process involving the assessment of RCTs, trial registries and regulatory reports for atopic and safety outcomes, as well as NRSIs investigating the association between pertussis immunisation and atopic diseases. Although there is no consensus regarding suitable search strategies for controlled NRSIs, we decided to incorporate a filter developed by <a href="./references#CD013682-bbs2-0141" title="WaffenschmidtS , Navarro-RuanT , HobsonN , HausnerE , SauerlandS , HaynesRB . Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE. Research Synthesis Methods2020;11(5):617–26. [DOI: 10.1002/jrsm.1425]">Waffenschmidt 2020</a> with the purpose to maximise sensitivity in the database searches. Through the review of the list of references of eligible studies, we found extended reports of the trials of <a href="./references#CD013682-bbs2-0010" title="Ciofi degli AttiML , OlinP . Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Developments in Biological Standardization1997;89:77–81. [PMID: 9272334]GustaffsonL , HallanderH , OlinP , ReizensteinE , Storsaeter, J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Swedish Institute for Infectious Disease Control, 1995. GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]HallanderH , AdvaniA , AlexanderF , GustafssonL , LjungmanM , PrattC , et al. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology2014;21(2):165–73. [DOI: 10.1128/CVI.00641-13]HallanderHO , GustafssonL , LjungmanM , StorsaeterJ . Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine2005;23(46):5359–64. [DOI: 10.1016/j.vaccine.2005.06.009]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]NCT00004799. Phase III randomized, double-blind, placebo-controlled study of acellular and whole-cell pertussis vaccines. clinicaltrials.gov/ct2/show/record/NCT00004799 (first posted 25 February 2000). NilssonL , KjellmanNI , StorsaeterJ , GustafssonL , OlinP . Lack of association between pertussis vaccination and symptoms of asthma and allergy. JAMA1996;275(10):760. [PMID: 8598591]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]OlinP . Efficacy trial of acellular pertussis vaccines; trial I. Developments in Biological Standardization1997;89:52–4. [PMID: 9333569]StorsaeterJ , HallnderHO , GustafssonL , OlinP . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine1998;16(20):1907–16. [DOI: 10.1016/s0264-410x(98)00227-8]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine2000;18(21):2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Gustafsson 1996</a> and <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a>, a conference proceeding with detailed safety data (<a href="./references#CD013682-bbs2-0015" title="MillerE , AshworthLA , RobinsonA , WaightPA , IronsLI . Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet1991;337(8733):70–3. [DOI: 10.1016/0140-6736(91)90735-8]MillerE , Ashworth L AE , RedheadK , ThorntonC , WaightPA , ColemanT . Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine1997;15(1):51–60. [DOI: doi: 10.1016/s0264-410x(96)00112-0]MillerE , MillerDL , AshworthLA , WaightPA , HarbertKA . Preliminary comparison of antibody responses and symptoms following primary immunization with British whole-cell and three acellular DTP vaccines. Proceedings of the Sixth International Symposium on Pertussis; 1990 Sep 26–28; Bethesda (MD)1990:303-9. ">Miller 1990</a>), cohort profiles and detailed descriptions of the outcome definitions (<a href="./references#CD013682-bbs2-0061" title="JedrychowskiW , WhyattRM , CamannDE , BawleUV , PekiK , SpenglerJD , et al. Effect of prenatal PAH exposure on birth outcomes and neurocognitive development in a cohort of newborns in Poland. Study design and preliminary ambient data. International Journal of Occupational Medicine and Environmental Health2003;16(1):21–9. [PMID: 12705714]Mrozek-BudzynD , MajewskaR , KieltykaA , AugustyniakM . Whole-cell pertussis vaccine (DTwP) has no influence on allergic diseases and atopic sensitization in children. Postepy Dermatologii i Alergologii2018;35(4):381–6. [DOI: 10.5114/ada.2018.77668]">Mrozek‐Budzyn 2018</a>; <a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a>), and the primary report of an ineligible study (<a href="./references#CD013682-bbs2-0033" title="GrüberC , WarnerJ , HillD , BauchauV . Early atopic disease and early childhood immunization--is there a link?Allergy2008;63(11):1464–72. [DOI: 10.1111/j.1398-9995.2008.01696.x]">Grüber 2008</a>). A study awaiting classification was cited in an assessment of safety data completed by the EMA (<a href="./references#CD013682-bbs2-0060" title="European Medicines Agency. Infanrix Hexa - EPAR- scientific discussion; 2005. Available at www.ema.europa.eu/en/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf. GlaxoSmithKline. A phase III, open randomised clinical study to assess the immunogenicity and reactogenicity of SBBiologicals’ Haemophilus influenzae type b conjugate vaccine co-administered with SB Biologicals’ combined diphtheria tetanus-acellular pertussis-hepatitis B-inactivated polio vaccine(DTPa-HBV-IPV) in one single injection or as two separate injections, in comparison with Pasteur-Mérieux-Connaugh't’s combined diphtheria-tetanus-whole-cell pertussis-inactivated polio Haemophilus influenzae type b vaccine (Pentacoq™) coadministered with SB Biologicals’ hepatitis B vaccine as two concomitant injections in opposite limbs, given to healthy infants as a primary vaccination course at 2, 3 and 4 months of age. No longer available. ">217744/025 (DTPa‐HBV‐IPV‐025)</a>). The final report of this trial was not available in the GSK trial registry when the searches were conducted, nor before the submission of this manuscript. We contacted authors of 12 studies requesting demographics, details on the interventions administered, or additional information regarding the study outcomes. However, it was not always possible to obtain the relevant data due to authors being seconded to work on coronavirus disease‐19 (COVID‐19) pandemic‐related roles, investigators being unable to access historical data (records unavailable), or due to non‐response to our requests. Nonetheless, we consider that our review process was robust. </p> </section> <section id="CD013682-sec-0124"> <h4 class="title">Applicability of evidence</h4> <p>One trial was included in our narrative synthesis of atopic outcomes (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>). This study was unable to detect a true difference in the cumulative incidence of atopic diseases, asthma or atopic dermatitis by 2.5 years old in children primed with wP, compared to those receiving aP‐only schedules. The diagnoses were made based on parental report using questionnaires, physical examination, medical records and/or evidence of IgE‐mediated sensitisation, However, it is plausible that some children labelled as 'asthmatic' by this trial, may have been transient wheezers in retrospect, and we believe that this phenotype is unlikely to be affected by wP priming. </p> <p>The incidence of SAEs following immunisation in infants primed with a first dose of either wP or aP was low. Although these findings support the safety of these vaccines, implementation of wP in countries where it is no longer the standard of care for preventing pertussis might be hindered by non‐serious adverse reactions which are more frequent after wP than aP vaccines, as described by a previous Cochrane Review (<a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a>), and more recently, by the systematic review of <a href="./references#CD013682-bbs2-0116" title="PattersonJ , KaginaBM , GoldM , HusseyGD , MuloiwaR . Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine2018;36(40):6007–16. [DOI: 10.1016/j.vaccine.2018.08.022]">Patterson 2018</a>. </p> </section> </section> <section id="CD013682-sec-0125"> <h3 class="title" id="CD013682-sec-0125">Quality of the evidence</h3> <section id="CD013682-sec-0126"> <h4 class="title">Atopic outcomes</h4> <p>We found four eligible studies reporting on atopic outcomes (one RCT and three NRSIs); however, pooling was not possible. The RCT was carried out in a country with low prevalence of IgE‐mediated food allergy (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>), and was statistically underpowered to detect a reduction in their chosen endpoints, except for a large reduction &gt; 50%. Therefore, the evidence for cumulative incidence of atopic disease at 2.5 years of age was downgraded by one level for indirectness, and two levels for imprecision. Similarly, it is uncertain whether wP may change the risk of atopic dermatitis or asthma by 2.5 years old, as the 95% CI around the point estimates were wide, and include the null effect. NRSIs were judged as serious or critical risk of bias due to confounding, missing data or both, and thus, were ineligible for a narrative synthesis. </p> </section> <section id="CD013682-sec-0127"> <h4 class="title">Safety outcomes</h4> <p>Except for four studies judged to be at high risk of bias (<a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a>; <a href="./references#CD013682-bbs2-0012" title="KitchinN , SouthernJ , MorrisR , BorrowR , FiquetA , BoisnardF , et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine2009;27(3):5096–102. [DOI: 10.1016/j.vaccine.2009.06.049]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70, Figure Flow diagram of subjects’ progress through the study; p 3966. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinN , SouthernJ , MorrisR , HemmeF , CartwrightK , WatsonM , et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine2006;24(18):3964–70. [DOI: 10.1016/j.vaccine.2006.02.018]KitchinNR , SouthernJ , MorrisR , HemmeF , ThomasS , WatsonMW , et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Archives of Disease in Childhood2007;92(1):11–6. [DOI: doi.org/10.1136/adc.2005.076109]">Kitchin 2006</a>; <a href="./references#CD013682-bbs2-0014" title="EMA/373868/2013. European Medicines Agency Hexacima assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf. EMA/373968/2013. European Medicines Agency Hexyon assessment report; March 2013. Available at www.ema.europa.eu/en/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf. MadhiSA , KoenA , Cutl, C, GroomeM , Santos-LimaE . Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatric Infectious Disease Journal2013;32(8):889–97. [DOI: 10.1097/INF.0b013e318292f7b1]MadhiSA , LopezP , ZambranoB , JordanovE , B'ChirS , NoriegaF , et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human Vaccines &amp; Immunotherapeutics2019;15(3):658–68. [DOI: 10.1080/21645515.2018.1546524]MadhiSA , MithaI , Cutl, C, GroomeM , Santos-LimaE . Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatric Infectious Disease Journal2011;30(4):e68–e74. [DOI: 10.1097/INF.0b013e31820b93d2]NCT00362336. Comparison of DTaP-IPV-Hep B-PRP~T combined vaccine to CombAct-HIB® concomitantly given with Engerix B® paediatric and OPV [Immunogenicity study of a DTaP-IPV-Hep B-PRP~T combined vaccine in comparison to CombAct-HIB® concomitantly administered with Engerix B® paediatric and OPV at 6, 10, and 14 Weeks of age in South African infants]. clinicaltrials.gov/ct2/show/results/NCT00362336 (first posted 10 August 2006). NCT01105559. Antibody persistence in healthy children after primary and booster DTaP-IPV-Hep B-PRP-T vaccine or control vaccine [Antibody persistence in healthy South African children after primary series and booster vaccination with an investigational (DTaP-IPV-Hep B-PRP-T) or control vaccines]. clinicaltrials.gov/ct2/show/NCT01105559 (first posted 16 April 2010). ">Madhi 2011</a>; <a href="./references#CD013682-bbs2-0021" title="ReinertP , FiquetA , ThomasS , SchuylemanA , WatsonM . Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Human Vaccines2006;2(5):215–21. [DOI: 10.4161/hv.2.5.3220]">Reinert 2006</a>), all the trials pooled for meta‐analysis of SAEs were assessed to be at unclear risk of bias. Overall, randomisation, allocation concealment and detection bias were poorly reported; however, most of these historical data were made available before the publication of the revised version of the CONSORT statement (<a href="./references#CD013682-bbs2-0109" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet2001;357(9263):1191–4. [PMID: 11323066]">Moher 2001</a>). This is perhaps why the minimally required reporting standards arising from stages where bias was likely to occur remained unmet. Therefore, omissions are likely to be a result of a lack of reporting, rather than that bias is actually present. </p> <p>The evidence regarding all‐cause SAE was judged as moderate (downgraded one level for imprecision), since a potential decrease or increase in the risk difference remains plausible, but unlikely to be clinically meaningful. No cases of encephalopathy were detected by seven primary series trials. Because this is a serious condition, we could not rule out a clinically meaningful difference and therefore, we judged the quality of the evidence as low (downgraded two levels for imprecision). Irrespective of these methodological caveats, our results support the safety of wP‐containing vaccines. </p> </section> </section> <section id="CD013682-sec-0128"> <h3 class="title" id="CD013682-sec-0128">Potential biases in the review process</h3> <p>We are confident that we have identified all the studies that compared wP versus aP in regards to the development of atopic diseases. We followed standard Cochrane methods to select studies for inclusion, data extraction, assessment of the risk of bias and used GRADE to determine the certainty of the evidence. </p> <p>We chose a follow‐up period of at least six months as an eligibility criterion, since the assessment of atopic conditions often requires confirmatory investigations. Furthermore, food sensitisation is likely to occur in the first months of life (possibly through low‐dose of cutaneous sensitisation (<a href="./references#CD013682-bbs2-0081" title="Du ToitG , SampsonHA , PlautM , BurksAW , AkdisCA , LackG . Food allergy: update on prevention and tolerance. Journal of Allergy Clinical Immunology2018;141(1):30–40. [PMID: 10.1016/j.jaci.2017.11.010]">Du Toit 2018</a>), and food allergic reactions usually require introduction of solid foods, which generally only occurs after six months old (especially for peanuts and tree nuts). Although we did not exclude any study reporting on atopic outcomes on the basis of the follow‐up period, some trials comparing the safety of primary vaccination series using wP versus aP did not meet the minimum follow‐up criterion and were therefore not included. The exclusion of these studies was unlikely to change the results or the certainty of the evidence, since these trials were small and unlikely to detect a true difference in the occurrence of SAEs with frequencies less than 2%. One out of three ongoing RCTs is systematically collecting data on our primary atopic and safety outcomes (<a href="./references#CD013682-bbs2-0062" title="ACTRN12617000065392. Optimising immunisation using mixed schedules (OPTIMUM): comparing allergic outcomes in infants following pertussis vaccination [A double-blind, randomised, controlled trial to compare allergic outcomes in children following vaccination with acellular pertussis antigen given at 2 months of age versus whole cell pertussis in the infant vaccine schedule]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000065392 (date submitted 15 December 2016). ">ACTRN12617000065392</a>), and the remaining studies are expected to report SAEs where occurring. Two studies 'awaiting classification' have not been included in our synthesis, creating a source of potential bias. The reasons for non‐inclusion are listed in the <a href="./references#CD013682-sec-0151" title="">Characteristics of studies awaiting classification</a> table, and encompass not being able to find the final report of an industry‐funded immunogenicity trial (<a href="./references#CD013682-bbs2-0060" title="European Medicines Agency. Infanrix Hexa - EPAR- scientific discussion; 2005. Available at www.ema.europa.eu/en/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf. GlaxoSmithKline. A phase III, open randomised clinical study to assess the immunogenicity and reactogenicity of SBBiologicals’ Haemophilus influenzae type b conjugate vaccine co-administered with SB Biologicals’ combined diphtheria tetanus-acellular pertussis-hepatitis B-inactivated polio vaccine(DTPa-HBV-IPV) in one single injection or as two separate injections, in comparison with Pasteur-Mérieux-Connaugh't’s combined diphtheria-tetanus-whole-cell pertussis-inactivated polio Haemophilus influenzae type b vaccine (Pentacoq™) coadministered with SB Biologicals’ hepatitis B vaccine as two concomitant injections in opposite limbs, given to healthy infants as a primary vaccination course at 2, 3 and 4 months of age. No longer available. ">217744/025 (DTPa‐HBV‐IPV‐025)</a>), or to confirm the age at which the first dose of pertussis‐containing vaccine was administered (<a href="./references#CD013682-bbs2-0061" title="JedrychowskiW , WhyattRM , CamannDE , BawleUV , PekiK , SpenglerJD , et al. Effect of prenatal PAH exposure on birth outcomes and neurocognitive development in a cohort of newborns in Poland. Study design and preliminary ambient data. International Journal of Occupational Medicine and Environmental Health2003;16(1):21–9. [PMID: 12705714]Mrozek-BudzynD , MajewskaR , KieltykaA , AugustyniakM . Whole-cell pertussis vaccine (DTwP) has no influence on allergic diseases and atopic sensitization in children. Postepy Dermatologii i Alergologii2018;35(4):381–6. [DOI: 10.5114/ada.2018.77668]">Mrozek‐Budzyn 2018</a>). </p> <p>Outcome data from <a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a> were synthesised narratively using a broader outcome domain (i.e. cumulative incidence of atopic disease at 2.5 years). The data were extracted from a bar chart using a web‐based data extraction tool (<a href="https://revman.cochrane.org/423619948848611473" target="_blank">WebPlotDigitizer 2020</a>). The same methods were implemented to extract the relevant data for diagnoses of asthma and atopic dermatitis. In spite of being more accurate compared to manual estimations, this method was not prespecified in our protocol, yet implemented as these critical data were not reported elsewhere. </p> <p>We generated contour‐enhanced funnel plots for the outcomes 'all‐cause mortality' and 'all‐cause SAEs'. In the first plot we did not detect additional sources of bias or asymmetry (<a href="https://osf.io/hmwpd/?view_only=7b27e3a2270f48c99c17787a45a6b913" target="_blank">Supplementary material 3</a>). In the second plot (<a href="#CD013682-fig-0006">Figure 6</a>), the trial of <a href="./references#CD013682-bbs2-0003" title="BlumbergDA , MinkCM , CherryJD , JohnsonC , GarberR , PlotkinSA , et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. Journal of Pediatrics1991;119(2):194–204. [DOI: doi.org/10.1016/s0022-3476(05)80727-9]BlumbergDA , PinedaE , CherryJD , CarusoA , ScottJV . The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent. American Journal of Diseases of Children1992;146(10):1148–50. [DOI: 10.1001/archpedi.1992.02160220034016]CherryJD , MortimerEA , HackellJG , ScottJV . Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Developments in Biological Standardization1991;73:51–8. [PMID: 1778334]StoutMG . U.S. clinical trials with Takeda acellular pertussis vaccine. Tokai Journal of Experimental and Clinical Medicine1988;13:21–8. [PMID: 2908521]">Blumberg 1991</a> , which was judged to be at high risk of bias due to high attrition rates, is represented as an outlier at the bottom right‐hand side. Overall, the plot suggests a lack of smaller studies reporting on SAEs. However, as larger studies did not find a difference regarding the occurrence of this outcome and the type of priming schedule, it appears unlikely that the inclusion of smaller studies would change the effect estimate. </p> <div class="figure" id="CD013682-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Contour‐enhanced funnel plot of comparison:  first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause  serious adverse events" data-id="CD013682-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Contour‐enhanced funnel plot of comparison:  first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause  serious adverse events </p> </div> </div> </div> <p>Due in part to the limitations posed by the COVID‐19 pandemic, we were unable to source the extended technical reports and analysis plans of the Sweden I and II efficacy, immunogenicity and safety trials (<a href="https://revman.cochrane.org/421643922681657684" target="_blank">Gustafsson 1996</a>; <a href="https://revman.cochrane.org/421643922681657815" target="_blank">Olin 1997</a>). These documents are cited by the scholarly work of pertussis vaccine researchers, and likely to include additional details on the safety data that had otherwise been summarised by the FDA in their regulatory report, as well as in peer‐reviewed publications. </p> <p>The number of SAEs in the trial of <a href="./references#CD013682-bbs2-0020" title="Anonymous. Whooping cough vaccine trial compares British whole cell vaccine and acellular vaccines. Communicable Disease Report1997;7(21):181. [PMID: 9505458]HeijbelH , Ciofi degli AttiM , HarzerE , LieseJ , PreziosiMP , RasmussenF , et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Developments in Biological Standardization1997;89:101–3. [PMID: 9272338]HeijbelH , RasmussenF , OlinP . Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Developments in Biological Standardization1997;89:99–100. [PMID: 9272337]OlinP , GustafssonL , RasmussenF , HallanderH , HeijbelH , GottfarbP . Efficacy trial of acellular pertussis vaccines: technical report trial II with preplanned analyses of efficacy, immunogenicity and safety. Swedish Institute for Infectious Disease Control (SMI-tryck)1997;116:1–70. OlinP , HallanderHO , GustafssonL , BarretoL , PoddaA . Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Developments in Biological Standardization1998;95:211–20. [PMID: 9855434]OlinP , RasmussenF , GottfarbP . Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. International Journal of Infectious Diseases1997;1(3):143–7. OlinP , RasmussenF , GustafssonL , HallanderHO , HeijbelH . Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet1997;350(9091):1569–77. [DOI: 10.1016/s0140-6736(97)06508-2]OlinP . Acellular pertussis vaccines - A question of efficacy. Journal of Hospital Infection1995;30(Suppl):503–7. [DOI: 10.1016/0195-6701(95)90055-1]TiruM , HallanderHO , GustafssonL , StorsaeterJ , OlinP . Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster [Vaccine]. 2000 18;21:2295–306. [DOI: 10.1016/s0264-410x(99)00539-3]US Food &amp; Drug Administration. Clinical review of biological license application - DAPTACEL (CPDT); April 2002. Available at www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103057.pdf. ">Olin 1997</a> was provided in both, regulatory data and peer‐reviewed publications. One of the peer‐reviewed articles included the number of children experiencing these events, but the data were not broken down by study arm. However, in some circumstances it was possible to match the number of children who met a specific endpoint (i.e. events described as life‐threatening or deaths), with their vaccination status as indicated in the FDA assessment of the safety data of this trial. These data points were included for synthesis. </p> <p>Due to paucity of studies, we could only undertake two out of three prespecified sensitivity analyses (i.e. excluding trials at high risk of bias, or those sponsored by pharmaceutical companies). Subgroup analyses were not possible for similar reasons. </p> <p>Four of our review authors were investigators of an included NRSI (<a href="https://revman.cochrane.org/421651323055802258" target="_blank">Estcourt 2020</a>) and five, are currently involved in <a href="https://revman.cochrane.org/421643922681657746" target="_blank">ACTRN12617000065392</a>, an ongoing study. The authors listed in the study of <a href="https://revman.cochrane.org/421651323055802258" target="_blank">Estcourt 2020</a> were not involved in the extraction of these data, nor did they participate in their risk of bias assessment. </p> </section> <section id="CD013682-sec-0129"> <h3 class="title" id="CD013682-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>A review investigating associations between childhood vaccination and allergy has been recently published (<a href="./references#CD013682-bbs2-0111" title="NavaratnaS , EstcourtMJ , BurgessJ , WaidyatillakeN , EnohE , LoweAJ , et al. Childhood vaccination and allergy: a systematic review and meta-analysis. Allergy 2021 Feb 11 [Epub ahead of print]. [DOI: 10.1111/all.14771]">Navaratna 2021</a>). In contrast with our review, RCTs and studies comparing pertussis immunisation with no vaccination or placebo were deemed eligible. Similarly, based on the trial of <a href="https://revman.cochrane.org/421643922681657805" target="_blank">Nilsson 1998</a>, the review of <a href="./references#CD013682-bbs2-0111" title="NavaratnaS , EstcourtMJ , BurgessJ , WaidyatillakeN , EnohE , LoweAJ , et al. Childhood vaccination and allergy: a systematic review and meta-analysis. Allergy 2021 Feb 11 [Epub ahead of print]. [DOI: 10.1111/all.14771]">Navaratna 2021</a> did not find an association between the type of pertussis‐containing vaccine and atopic outcomes. </p> <p>As part of the development of the WHO pertussis vaccine position paper, a Strategic Advisory Group of Experts (SAGE) on Immunisation summarised the certainty of the evidence on the safety of wP and aP vaccine formulations in immunocompetent infants and children under seven years old (<a href="https://revman.cochrane.org/424182646855010791" target="_blank">WHO 2015b</a>; <a href="./references#CD013682-bbs2-0147" title="World Health Organization. Pertussis vaccines position paper. Table III: Pertussis vaccine evidence to recommendations table. www.who.int/immunization/position_papers/PertussisGradeTable3.pdf?ua=1 (accessed 11 April 2021).">WHO 2015c</a>). Where wP was assessed as the intervention, the comparison was no vaccine or "control"; similarly, where aP vaccine formulations were included as the reference, no vaccine or "control" were chosen as the comparator. In either case, the evidence was gathered using an inclusive principle. The assessments of the SAGE are available as qualitative statements using GRADE, and subsequently summarised as recommendations using standard decision domains (i.e. the certainty of the evidence; balance of clinically important outcomes and harms; values and preferences; and resource implications). The incidence of SAEs following vaccination with wP versus comparator, or aP versus comparator was described as "low"; for each comparison, the risk of this outcome was reported as "not significant", and the certainty of the evidence as "high" (<a href="./references#CD013682-bbs2-0146" title="World Health Organization. Pertussis vaccines position paper. GRADE Table 2. Safety of pertussis vaccines in immunocompetent infants and children. www.who.int/immunization/position_papers/PertussisGradeTable2.pdf?ua=1 (accessed 11 April 2021).">WHO 2015b</a>). This is in contrast with the certainty of our findings, which was judged to be moderate, and restricted to the comparison of a first dose of wP versus aP in infants younger than six months, who were followed up for at least six months. Despite these differences, the findings of our review are consistent with the current recommendations of the WHO, which upholds the continued use of wP‐based primary series as part of national immunisation programmes. </p> <p>A previous Cochrane Review compared encephalopathy and mortality due to any cause in recipients of aP versus wP vaccine formulations using a Mantel‐Haenszel random‐effects model (<a href="https://revman.cochrane.org/417439426798693191" target="_blank">Zhang 2014</a>). In spite of eligibility being restricted to double‐blind RCTs irrespective of the length of follow‐up, we did not find a meaningful difference between the interpretation of their meta‐analysis for all‐cause mortality (risk ratio (RR) 1.14, 95% CI 0.82 to 1.60; I<sup>2</sup> = 0%; 122,451 children, 16 studies; RR and CI calculated using a first dose of wP as the intervention versus a first dose of aP as the comparator) and ours (Mantel‐Haenszel fixed‐effect model without continuity correction; 1.01 (95% CI 0.71 to 1.45; I<sup>2</sup> = 0%; 134,541, children, 18 studies; <a href="#CD013682-fig-0005">Figure 5</a>). The review of <a href="./references#CD013682-bbs2-0150" title="ZhangL , PrietschSO , AxelssonI , Halperin, SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD001478. [DOI: 10.1002/14651858.CD001478.pub6]">Zhang 2014</a> did not find any cases of encephalopathy following a primary series of wP (32,161 children) versus aP (81,601). Similarly, no cases of encephalopathy were recorded among the children included in our review of seven primary series RCTs (n<sub>wP</sub>= 32,268; n<sub>aP</sub> = 83,003), and a booster dose study with 2 years of safety follow‐up (n<sub>wP</sub>= 23; n<sub>aP</sub> =18). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013682-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD013682-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: judgement of the review authors about each risk of bias item for each included randomised controlled trial" data-id="CD013682-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: judgement of the review authors about each risk of bias item for each included randomised controlled trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias: 'traffic light' plot of the domain‐level judgements for each individual result of non‐randomised studies of interventions according to the ROBINS‐tool" data-id="CD013682-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias: 'traffic light' plot of the domain‐level judgements for each individual result of non‐randomised studies of interventions according to the ROBINS‐tool </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause serious adverse events" data-id="CD013682-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause mortality" data-id="CD013682-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Contour‐enhanced funnel plot of comparison:  first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause  serious adverse events" data-id="CD013682-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Contour‐enhanced funnel plot of comparison:  first dose of wP versus first dose of aP before 6 months of age. Outcome: all‐cause  serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 1: Cumulative incidence of atopic disease at 2.5 years" data-id="CD013682-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 1: Cumulative incidence of atopic disease at 2.5 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 2: Diagnosis of asthma by 2.5 years" data-id="CD013682-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 2: Diagnosis of asthma by 2.5 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 3: Diagnosis of atopic dermatitis by 2.5 years" data-id="CD013682-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 3: Diagnosis of atopic dermatitis by 2.5 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 4: Diagnosis of encephalopathy" data-id="CD013682-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 4: Diagnosis of encephalopathy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 5: All‐cause serious adverse events (following a booster dose of aP)" data-id="CD013682-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 5: All‐cause serious adverse events (following a booster dose of aP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013682-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/urn:x-wiley:14651858:media:CD013682:CD013682-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: First dose of wP versus first dose of aP, Outcome 6: Diagnosis of encephalopathy (following a booster dose of aP)" data-id="CD013682-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_t/tCD013682-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: First dose of wP versus first dose of aP, Outcome 6: Diagnosis of encephalopathy (following a booster dose of aP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/media/CDSR/CD013682/image_n/nCD013682-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013682-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants younger than six months of age<br/><b>Setting:</b> paediatric and immunisation clinics, vaccine treatment units attached to academic institutions and healthcare centres. The trials were carried out in 11 countries across North and South America, Europe, Sub‐Saharan Africa and South East Asia<br/><b>Intervention:</b> first dose of whole‐cell pertussis vaccine (wP)<br/><b>Comparison:</b> first dose of acellular pertussis vaccine (aP) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow‐up</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with first dose of acellular pertussis vaccine (aP)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with first dose of whole‐cell pertussis vaccine (wP)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence of atopic disease at 2.5 years old</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>It remains uncertain whether a first dose of wP, compared to aP, may prevent atopic diseases (RR 0.85, 95% CI 0.62 to 1.17). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of IgE‐mediated food allergy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0<br/>(studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>One study reported this (<a href="./references#CD013682-bbs2-0019" title="AalberseRC , GrüberC , LjungmanM , KakatS , WahnU , NiggemannB , et al. Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. Pediatric Allergy and Immunology2019;30(8):841–7. [DOI: 10.1111/pai.13113]GustafssonL , HallanderHO , OlinP , ReizensteinE , StorsaeterJ . A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine1996;334(6):349–55. [DOI: 10.1056/NEJM199602083340602]NilssonL , GrüberC , GranströmM , BjörksténB , Kjellman N-I. Pertussis IgE and atopic disease. Allergy1998;53(12):1195–201. [DOI: 10.1111/j.1398-9995.1998.tb03841.x]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):734–8. [DOI: doi.org/10.1001/archpedi.152.8.734]NilssonL , KjellmanNI , BjörksténB . A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Archives of Pediatrics &amp; Adolescent Medicine1998;152(8):Figure, Atopic manifestations in 669 children during the first 2 1/2 years of age in relation to type of pertussis vaccine; p. 736. NilssonL , Kjellman N-I, BjorkstenB . Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Archives of Pediatrics &amp; Adolescent Medicine2003;157(12):1184–9. [PMID: 10.1001/archpedi.157.12.1184]">Nilsson 1998</a>) as part of a broader outcome domain (i.e. cumulative incidence of atopic disease at 2.5 years old; reported in row above). However, it was not possible to obtain the data on incidence of IgE‐mediated food allergy specifically by study arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of asthma</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>It remains uncertain whether a first dose of wP, compared to aP, may prevent asthma (RR 1.04, 95% CI 0.59 to 1.82). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of anaphylaxis (not vaccine associated)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>38,072<br/>(15 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.78 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1,000<br/>(3 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diagnosis of encephalopathy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>115,271 <br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 100,000<br/>(5 fewer to 12 more)<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval;<b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the evidence by one level due to indirectness (study carried out in the late 1990s, in a country with low prevalence of IgE‐mediated food allergy) </p> <p><sup>2</sup> We downgraded the evidence by two levels due to imprecision (single study, statistically underpowered to detect a reduction in its chosen endpoints, except for a very large reduction &gt; 50%) </p> <p><sup>3</sup> We downgraded by one level for indirectness, as it is plausible that children diagnosed with 'asthma' by 2.5 years old, may have been 'transient (episodic) wheezers'. We believe that the risk of developing transient wheeze in early childhood is unlikely to be affected by wP priming </p> <p><sup>4</sup> We downgraded the certainty of the evidence by one due to imprecision (the 95% CI ranges from a potential decreased to a potential increased risk, unlikely to be clinically meaningful) </p> <p><sup>5</sup> Although the 95% CI around the absolute difference is narrow, we could not rule out a clinically meaningful difference and therefore, we rated down two levels for imprecision </p> <p><sup>6</sup> 95% CI calculated using the score method (<a href="./references#CD013682-bbs2-0112" title="NewcombeRG . Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in medicine1998;17(8):873-90. [PMID: 9595617]">Newcombe 1998</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Efficacy and safety of a first dose of whole‐cell pertussis vaccine compared to a first dose of acellular pertussis vaccine for the prevention of atopic diseases in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of challenge‐proven IgE‐mediated food allergy before 15 years old</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriately adjusted for surrogates of vaccine availability (date of birth and jurisdiction at vaccination) </p> <p>Potentially insufficient adjustment for socioeconomic status. Family history of atopy and breastfeeding could not have  influenced the allocation to the intervention as this was largely dependent on vaccine availability. The method used to minimise confounding was direct matching </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This is a retrospective case‐control study. The selection of cases was based on the outcome of interest. The exposure distribution in the controls is likely to represent the exposure status of the overall cohort, as controls were selected from the Australian Immunisation Register irrespective of their past or future case status  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was well‐defined and based on information collected at the time of the intervention  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information reported  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The association between vaccination status and challenge‐proven IgE‐mediated food allergy was tested through a sensitivity analysis, carried out according to the study protocol. Therefore, outcome data were only available for a non‐random subset of cases with a history of food allergic reaction coupled with IgE‐mediated sensitisation to the food of interest and a positive oral food challenge. </p> <p>A small number of children were excluded due to missing data on the exposure status. These data were likely to be missing at random </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome assessors reviewed the medical records while blinded to the vaccination status. They determined whether a child met the primary outcome (clinical criteria of food allergy and evidence of sensitisation to the food that may have caused the allergic reaction), and whether there was a clinical record of a positive oral food challenge to that food at any time. </p> <p>During the follow‐up period, vaccination status would not have influenced the decision to challenge a child with the food of interest<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study data were analysed according to a prespecified sensitivity analysis.</p> <p>There is no evidence of selective reporting.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This risk of bias assessment was based on the data included in a sensitivity analysis (i.e. a non‐random subset of cases). </p> <p>There are some concerns regarding missing outcome data, insufficient adjustment for socioeconomic status and lack of adjustment by birth order </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of challenge‐proven IgE‐mediated food allergy before 15 years old</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at five yearsa </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information</p> <p>available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome data were available for nearly all children.<sup>b</sup>A small proportion of children was excluded due to incomplete information on the exposure of interest </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to have been influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias judgements are also applicable for the outcomes: diagnosis of asthma (current asthma) at 18 months and 3 years </p> <p><sup>b</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0016"> <li> <p>Current asthma at 18 months: wP = 0/293; 0.00%. aP = 1/204; 0.49%</p> </li> <li> <p>Current asthma at 3 years: wP = 9/293; 3.07%. aP= 8/204; 3.92%</p> </li> <li> <p>Current asthma at 5 years:  wP = 15/293; 5.12%. aP = 14/204; 6.86%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at five yearsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at eight years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by  knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0017"> <li> <p>Current asthma by 8 years: wP = 59/293; 20.14%. aP = 30/204; 14.71%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at eight years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 11.5 years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status is well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is higher in aP vaccinees than in recipients of wP. <sup>a</sup> </p> <p>However, this is unlikely to be related to the exposure status. The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by  knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0018"> <li> <p>Current asthma by 11.5 years: wP = 83/293; 28.3%. aP = 76/204; 37.25%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 11.5 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 14 years</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0024" title="GardenFL , ToelleBG , MihrshahiS , WebbKL , AlmqvistC , ToveyER , et al. Cohort profile: the Childhood Asthma Prevention Study (CAPS). International Journal of Epidemiology2018;47(6):1736–6k. [DOI: 10.1093/ije/dyy078]MarksGB , MihrshahiS , KempAS , ToveyER , WebbK , AlmqvistC , et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. Journal of Allergy and Clinical Immunology2006;118(1):53–61. [PMID: 10.1016/j.jaci.2006.04.004]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. [DOI: doi.org/10.1111/pai.13300]ToelleBG , GardenFL , McIntyrePB , WoodN , MarksGB . Pertussis vaccination and allergic illness in Australian children. Pediatric Allergy and Immunology2020;31(7):857–61. Supplementary material. Table 3. Comparison of atopy and allergic illness in children who received first dose of wP vs aP. Outcomes for years 1.5, 3 and 14 only. ToelleBG , GardenFL , NgKK , BelousovaEG , AlmqvistC , CowellCT , et al. Outcomes of the childhood asthma prevention study at 11.5 years. Journal of Allergy and Clinical Immunology2013;132(5):1220–2.e3. [DOI: 10.1016/j.jaci.2013.06.005]ToelleBG , NgKK , CrisafulliD , BelousovaEG , AlmqvistC , WebbK , et al. Eight-year outcomes of the childhood asthma prevention study. Journal of Allergy and Clininical Immunology2010;126(2):388–9.e1–3. [DOI: 10.1016/j.jaci.2010.04.031]">Toelle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Serious  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation to the intervention was largely dependent on vaccine availability, as described in <a href="./references#CD013682-bbs2-0007" title="EstcourtMJ , CampbellDE , GoldMS , RichmondP , AllenKJ , QuinnHE , et al. Whole-cell pertussis vaccination and decreased risk of IgE-mediated food allergy: a nested case-control study. Journal of Allergy and Clinical Immunology. In practice2020;8(6):2004–14. [DOI: 10.1016/j.jaip.2019.12.020]EstcourtMJ , MarshJA , CampbellDE , GoldMS , AllenKJ , RichmondP , et al. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open2018;8(1):e020232. [DOI: 10.1136/bmjopen-2017-020232]NCT02490007. Case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy. clinicalTrials.gov/show/NCT02490007 (first posted 3 July 2015). ">Estcourt 2020</a>. The authors adjusted for breastfeeding status, sex, house dust mite avoidance and omega‐3 supplementation; however, these variables were unlikely to have influenced the assignment of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is high but balanced across the study groups.<sup>a</sup> The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This analysis was declared post‐hoc. However, there is no evidence of selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0019"> <li> <p>Current asthma by 14 years: wP = 105/293; 35,84%. aP= 72/204; 35.29%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of asthma (current asthma) at 14 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of IgE‐mediated food allergy (on the basis of either a compatible clinical history or oral food challenge) by 10 yearsa </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaccine allocation is described as 'almost at random, depending on the supply of the particular vaccine, avoiding potential biases due to secular trends in the risk of developing atopic disease'. </p> <p>The authors defined family history of asthma/hay fever, breastfeeding and sex as potential confounders; however, they were unlikely to have influenced the assignment of the study vaccines. Adjustment was made via multivariable binomial regression. No adjustment by date of birth, birth order and socioeconomic status was performed, 'as the number of cases was not sufficiently robust' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in the study.</p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome data were available for nearly all children.<sup>b</sup> A small proportion of children was excluded due to incomplete information on the exposure of interest </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not find the protocol of this study. However, there is no evidence of selective reporting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Also applicable for the outcome: diagnosis of asthma by 3 years </p> <p><sup>b</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0020"> <li> <p>Diagnosis of challenge proven IgE‐mediated food allergy: wP = 4/595; 0.67%. aP = 1/224; 0.45% </p> </li> <li> <p>Diagnosis of asthma by 3 years: wP = 35/595; 5.88%. aP = 20/224; 8.93%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I assessment for: first dose of wP versus aP vaccine before 6 months of age. Outcome: diagnosis of IgE‐mediated food allergy (on the basis of either a compatible clinical history or oral food challenge) by 10 yearsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013682-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of asthma by 10 years of age</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to confounding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of study participants into the study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in classification of interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias due to missing data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias in selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013682-bbs2-0025" title="Perez ChaconG . Re: Query re: No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001–2002 [personal communication]. Email to PJ Turner and C Venter 31 January 2021. VenterC , StoweJ , AndrewsN , MillerE , TurnerPJ . No association between atopic outcomes and pertussis vaccine given in children born on the Isle of Wight 2001–2002. Journal of Allergy and Clinical Immunology. In Practice2016;4(6):1248–50. [DOI: 10.1016/j.jaip.2016.06.005]">Venter 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rationale for judgement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaccine allocation is described as 'almost at random, depending on the supply of the particular vaccine, avoiding potential biases due to secular trends in the risk of developing atopic disease'. </p> <p>The authors defined family history of asthma/hay fever, breastfeeding and sex as potential confounders; however, they were unlikely to have influenced the assignment of the study vaccines. Adjustment was made via multivariable binomial regression. No adjustment by date of birth, birth order and socioeconomic status was performed, 'as the number of cases was not sufficiently robust' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children who would have been eligible for the target trial were included in this cohort study. </p> <p>The start of the follow‐up period coincides with the start of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intervention status was well‐defined and based on information collected at the time of the administration of the study vaccines </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no information available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of missing data is high, but balanced across the study groups.<sup>a</sup> The reported analysis was unlikely to have removed the risk of bias arising from missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The methods of outcome assessment were comparable across the intervention groups and unlikely to be influenced by knowledge of the intervention received. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not find the study protocol or statistical analysis plan of this study. However, there is no evidence of selective reporting<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This study cannot be considered comparable to a well‐performed RCT, as there is potential for confounding, and concerns abound missing data<br/> <br/>  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Proportion of missing outcome data </p> <p> <ul id="CD013682-list-0021"> <li> <p>Diagnosis of asthma by 10 years: wP = 259/595; 43.53%. aP = 112/224; 50.00%</p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I assessment for: first dose of whole‐cell versus acellular pertussis vaccine before 6 months of age. Outcome: diagnosis of asthma by 10 years of age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/full#CD013682-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013682-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">First dose of wP versus first dose of aP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cumulative incidence of atopic disease at 2.5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Diagnosis of asthma by 2.5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Diagnosis of atopic dermatitis by 2.5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Diagnosis of encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause serious adverse events (following a booster dose of aP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Diagnosis of encephalopathy (following a booster dose of aP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">First dose of wP versus first dose of aP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013682.pub2/references#CD013682-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013682.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013682-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013682-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013682-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013682-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="pl#CD013682-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013682-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013682-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013682\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013682\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013682\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013682\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013682\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013682.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013682.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013682.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013682.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013682.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726599789"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013682.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726599793"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013682.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e97958932f3c9',t:'MTc0MDcyNjYwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 